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ABSTRACT OF THE DISSERTATION
Canonical and Noncanonical Mechanisms of Resistance to Arginine Starvation in Cancer
by
Leonard Rogers
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2022
Professor Brian Van Tine, Chair
The enzyme argininosuccinate synthetase 1 (ASS1) catalyzes the condensation of citrulline and
aspartate into argininosuccinate as part of the urea cycle and citrulline-nitric oxide cycle. This
reaction is essential for mammals to synthesize the amino acid arginine, which is required for all
cells. Nearly all human tissues express at least some ASS1, but they import most of their arginine
from the extracellular space after it is produced and released by the kidneys. Most solid tumors
lack a functional level of ASS1, including over 85% of sarcomas, which are cancers of
connective tissues. Published evidence suggests that this provides a proliferation advantage by
reducing the consumption of aspartate by ASS1, resulting in a larger supply of aspartate to be
used in the production of pyrimidines for nucleic acid synthesis. However, ASS1 deficiency
causes these cancers to rely on extracellular arginine for survival and growth, which can be
targeted through arginine deprivation therapy. PEGylated arginine deiminase (ADI-PEG20), an
enzymatic drug that degrades extracellular arginine to citrulline, is the most widely used arginine
deprivation therapy, currently being tested in many clinical trials.
While often effective at slowing growth, many cancers, especially sarcomas, gain resistance to
ADI-PEG20 in the long term by upregulating their expression of ASS1 and gaining the ability to
x

synthesize arginine from the now abundant citrulline. This is so common because the ASS1 gene
is almost always transcriptionally repressed rather than being deleted or mutated. However, it
takes time to increase ASS1 expression sufficiently. In the short term, cells also upregulate
autophagy to provide a temporary source of arginine for protein translation and survival. These
canonical mechanisms have been studied extensively, and ASS1 re-expression is the only
published pathway of long-term resistance to arginine deprivation therapy. Many other pathways
could theoretically provide long-term resistance to ADI-PEG20, but none have yet been shown
to do so.
To determine whether ASS1 deficiency truly provides an advantage to sarcomas in vivo, a
murine model of spontaneous sarcomas was developed with Ass1 knocked out (KO). Conditional
Ass1 KO mice did not develop tumors sooner than control mice, nor did their tumors grow faster.
In fact, tumors that expressed high levels of ASS1 initiated earlier and grew faster. These data
cast doubt on the importance of previous findings explaining the advantages of ASS1 silencing;
they suggest that the main reason for a lack of ASS1 in sarcomas may be inheritance from their
tissues of origin. The apparent advantage conferred by ASS1 overexpression in these tumors
remains unexplained but is a good target for future study.
To characterize the kinetics and heterogeneity of the development of resistance to ADI-PEG20 in
ASS1-deficient cancers, a sensor system was developed to monitor the availability of
intracellular arginine for protein translation. The sensor consists principally of a genomically
integrated gene encoding a reporter protein downstream of an arginine-rich region. Sensor
expression is thereby regulated at the translational level, as ribosomes stall or move more slowly
at the arginine-rich region, causing reporter protein expression to decrease when arginine
supplies are low. Nuclear localization of the reporter and automated imaging allowed tracking of
xi

resistance to arginine deprivation in individual live cells. It was found that all ASS1-deficient
cancer cells reduced their expression of the sensor when treated with ADI-PEG20 in vitro,
followed by a period of heterogeneous recovery of expression. The timing and magnitude of
resistance varied widely among individual cells. However, the sensor expression profile was
quite different in vivo, as ADI-PEG20 unexpectedly had no impact on the expression of the
arginine sensor even while tumor growth was slowed.
Ass1 KO tumor cell lines generated from the mouse model described above also did not decrease
their expression of the arginine sensor when grafted into syngeneic mice and treated with ADIPEG20. Unexpectedly, these tumors grew robustly through arginine deprivation therapy in vivo,
where they were expected to die as they do in vitro. This suggested that the tumor
microenvironment lent strong growth support to the tumors by supplying arginine. This
hypothesis was further supported with in vitro experiments showing that ASS1-competent
fibroblasts could support growth of Ass1 KO tumor cells during ADI-PEG20 treatment. This
growth support effect was found to likely be mediated through the uptake of fibroblast-derived
extracellular vesicles (EVs) by macropinocytosis into cancer cells, followed by degradation and
recycling of the EV components by autophagy/lysosomal degradation to yield free arginine for
the cancer cells to use. Inhibition of this growth support phenomenon was shown to be possible
by targeting either EV production and macropinocytosis or autophagy both in vitro and in vivo.
These experiments uncovered a novel mechanism of resistance to arginine deprivation therapy,
completely independent of intrinsic ASS1 expression, which was previously thought necessary.
Further, these results highlight the importance and previously unknown magnitude of the ability
of the tumor microenvironment to metabolically support tumors. Finally, this work has opened
multiple promising avenues for future research that deserve to be explored.
xii

Chapter 1: Introduction: Innate and
Adaptive Resistance Mechanisms to Arginine
Deprivation Therapies in Sarcoma and Other
Cancers
This chapter is based on the publication listed below and has been reformatted to adhere to
dissertation guidelines.
Rogers, L. C. & Van Tine, B. A. Innate and adaptive resistance mechanisms to arginine
deprivation therapies in sarcoma and other cancers. Cancer Drug Resist (2019)
doi:10.20517/cdr.2019.49.
Contributing authors are Leonard Rogers and Brian Van Tine.

1.1 Abstract
Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1 (ASS1)
that is necessary for synthesis of L-arginine. These cancers must import arginine for survival and
growth, and this reliance can be targeted by arginine-degrading extracellular enzymatic drugs,
most commonly PEGylated arginine deiminase. These enzymes can become targets of the
immune system, reducing their effectiveness, but PEGylation improves the in vivo stability.
Arginine deprivation causes cell death in some cancers, but others gain resistance by expressing
ASS1 after a starvation response is induced. Other resistance mechanisms are possible and
explored, but these have not been observed specifically in response to arginine deprivation.
Future studies, especially focusing on the mechanisms of ASS1 upregulation and metabolic
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adaptations, may yield insights into preventing or taking advantage of resistance adaptations to
make arginine deprivation therapy more effective.

1.2 Introduction
Our understanding of metabolic therapies and how to use them clinically is rapidly evolving.
Current therapies based on tumor metabolism are focused on glutaminase inhibitors, isocitrate
dehydrogenase (IDH) inhibitors, pyruvate transport via monocarboxylate transporter 1 (MCT1),
and amino acid-degrading enzymes that target asparagine or arginine. It is the ability to
systematically degrade arginine and how to apply this clinically that is the focus of this review.
Currently, arginine starvation results in an adaptive metabolic reprogramming that renders cells
resistant to arginine starvation1-3. By better understanding the mechanisms of this adaptation,
successful therapeutic strategies based on arginine starvation and its related biomarker ASS1 will
result.
Amongst the more commonly arginine auxotrophic cancers are all the subtypes of sarcoma.
Regardless of histology, about 88% lack significant expression of argininosuccinate synthetase 1
(ASS1)1. This finding is not unique to sarcoma, as most solid tumors, including many
melanomas, bladder cancers, prostate cancers, small cell lung cancers, and hepatocellular
carcinomas, are deficient in this enzyme4-9.
Sarcomas often originate in muscle and bone, and these two tissues, along with the heart and
lungs, are among the lowest ASS1 mRNA-expressing tissues in the body10-12. The high incidence
of ASS1 silencing in sarcoma may be a consequence of its tissues of origin, but this is a subject
of ongoing research. This explanation is also supported by the fact that the ASS1 gene is rarely
mutated or deleted in cancer. Rather, its transcription is regulated by epigenetic modifications
2

and transcription factors13-16. A common mechanism of ASS1 silencing is hypermethylation of its
promoter region, causing decreased transcription13,14,16. Some cancers have also shown
competition between the repressive HIF-1α and activating c-Myc transcription factors binding to
the E-box of the ASS1 promoter15. These are all reversible regulation mechanisms that can
dynamically respond when the cell is stressed by a lack of arginine. Further work to fully
understand the nature of ASS1 silencing in sarcomas is ongoing.

1.2.1 Urea Cycle
The urea cycle in humans, shown in full in Figure 1.1, takes place mainly in the liver as a way to
convert waste ammonia to urea. Ammonia is first converted to carbamoyl phosphate by
condensation with carbonic acid and a phosphate group, a reaction catalyzed by carbamoyl
phosphate synthetase I (CPS1)17. The carbamoyl phosphate is then condensed with ornithine
with the loss of inorganic phosphate, catalyzed by ornithine transcarbamoylase (OTC), forming
citrulline17. ASS1 then catalyzes the condensation of aspartate with citrulline to
form argininosuccinate17. Argininosuccinate lyase (ASL) then cleaves argininosuccinate into
fumarate and arginine17. The arginine is subsequently hydrolyzed into ornithine and urea by
arginase 1 (ARG1)17.
Although urea production is its main purpose, the cycle is not isolated and exchanges
intermediates with other pathways in the cell. In fact, many cells outside the liver do not perform
the full cycle but use portions for other functions, namely to produce nitric oxide (NO) and
synthesize arginine, as shown in Figure 1.1. In adult humans, the kidneys import extracellular
citrulline to synthesize arginine for the rest of the body18. Because of this, most cells in the body
have no need to produce arginine, but many still employ part of the urea cycle to produce NO.
This is achieved by the enzyme NO synthase (NOS), using arginine and oxygen to produce NO
3

and citrulline19. The citrulline can then be recycled to arginine by ASS1 and ASL, in what is
sometimes called the citrulline-NO cycle19.

1.2.2 Functional Consequences of ASS1 Silencing
There are many possible benefits of suppressing ASS1. The leading hypothesis is that silencing
this gene may accelerate cellular growth by causing an increase in available aspartate20.
Aspartate is consumed in the essentially irreversible reaction catalyzed by ASS1 to ligate
citrulline and aspartate (Figure 1.1)17. ASS1 deficiency therefore increases levels of aspartate,
which is needed to make pyrimidines for nucleotide synthesis, allowing cell proliferation. In fact,
the lethal metabolic disorder citrullinemia type I, caused by ASS1 deficiency or mutation, results
in increased pyrimidine synthesis and proliferation20. Supporting this hypothesis are multiple
studies that have shown aspartate to be a key limiting metabolite for the growth of cancer
cells21,22.
Another possibility is that ASS1 downregulation helps maintain a higher intracellular pH under
acidic stress in the tumor microenvironment23. This happens when the urea cycle cannot function
due to ASS1 loss, leaving basic ammonia free in the cells to scavenge protons. The net
consequence of this is increased intracellular pH. Recently, another beneficial role has been
proposed for ammonia in cancer, as its nitrogen may be directly incorporated into amino acids to
maximize growth efficiency24. There are likely other beneficial reasons that are yet to be
elucidated.
ASS1 deficiency is also predicted to decrease cellular levels of fumarate, a product of the urea
cycle downstream of ASS1. Although this metabolite seems to be unexplored in the context of
ASS1 deficiency, any decrease is unlikely to be beneficial, considering that excess fumarate has
been found to induce epithelial-to-mesenchymal-transition (EMT) and promote cancer
4

progression25. ASS1 is also essential in the citrulline-NO cycle that produces nitric oxide (NO)
for signaling19. However, the citrulline-NO cycle is not necessary, as the substrate needed for
NO synthesis is arginine, which can normally be imported from extracellular sources. Regardless
of the advantages conferred by ASS1 deficiency, this state renders the cells sensitive to arginine
deprivation in a targetable way.
Multiple enzymes are capable of targeting ASS1-deficient cells by degrading arginine in the
bloodstream. Arginine decarboxylase (ADC) can be found in bacteria, plants, and mammals26.
ADC converts arginine to agmatine, which is toxic to normal cells and cannot be converted back
to arginine, thus limiting the therapeutic potential of this enzyme26. Nitric oxide synthase (NOS)
could also theoretically be used to degrade arginine in the blood, but the increased NO levels
may have unintended signaling effects, and NOS has not been used in this fashion to our
knowledge. Recombinant human arginase I has been adapted as a drug to degrade extracellular
arginine26. The effectiveness has been greatly improved over time by several modifications, but
arginase is less commonly used as a therapy than the following enzyme because of its lower
affinity for arginine6,26. The most widely used of the arginine-degrading enzymes is arginine
deiminase, an enzyme found in many microbial organisms that hydrolyzes arginine into citrulline
and ammonia6,27. Arginine deiminase has been conjugated to polyethylene glycol of 20 kDa
average size (ADI-PEG20), helping to increase its in vivo half-life drastically28.
This drug is being tested in multiple clinical trials and is very promising for multiple reasons.
First, it deprives the entire body of arginine regardless of whether the site is accessible, as
demonstrated by its efficacy against intracranial glioblastoma, which is protected by the blood
brain barrier29. Importantly, ADI-PEG20 has strong effects on ASS1-deficient tumors while
having only benign side effects of injection site rash and increased uric acid levels. These
5

differing effects on normal tissues versus tumors can be at least partially explained by the fact
that most cells in the body express ASS1. The liver and kidneys have extremely high levels of
the enzyme, as the liver performs the urea cycle for the body, and the kidneys produce excess
arginine to export to the blood18. Most other tissues express varying levels of ASS1 for less clear
reasons, but it may be to carry out the citrulline-NO cycle19. As a result, most tissues can import
extracellular citrulline (a product of the ADI-PEG20 reaction) and synthesize arginine for
survival. Further explaining the more severe response to ADI-PEG20 in cancer specifically is the
increased rate of growth in tumors. While heart, lung, muscle, and bone express very low levels
of ASS1, these tissues are relatively static in their growth and therefore unaffected compared to
rapidly proliferating cancer cells. When starved of arginine, ASS1-deficient cancers are forced
into cytostasis and have been shown to rely partially on autophagy for survival1. Other methods
of arginine acquisition likely also play a part and will be discussed later.

1.3 Resistance
1.3.1 Adaptive Resistance
Some ASS1-deficient cancers undergo cell death when starved of arginine by ADI-PEG20, but
many others gain resistance to arginine deprivation1-3. This is especially common in sarcomas, as
they usually do not die as a consequence of arginine starvation1,2. The most obvious pathway to
resistance is upregulation of ASS1 expression. Indeed, this is the only cellular long-term
resistance mechanism that has been confirmed to occur in response to ADI-PEG201,6,15,30. This
path is open to nearly every ASS1-deficient cancer, as mutation or deletion of ASS1 is rare
compared to transcriptional silencing. Virtually all regulation of ASS1 has been found at the
transcriptional level, and the mechanisms by which ASS1 is upregulated in response to arginine
deprivation are the subject of much research.
6

Figure 1.2 illustrates the fully repressed and fully active states of the ASS1 promoter and shows
how arginine deprivation can lead to increased ASS1 expression and resistance to ADI-PEG20.
In ASS1-deficient lymphoid malignancies, demethylation of the ASS1 promoter with a
demethylating agent has been shown to rescue cells from ADI-PEG20 treatment13. More
importantly, ASS1-deficient mesothelioma cells were shown to autonomously demethylate their
ASS1 promoter to gain resistance31. However, more research has focused on the HIF-1α/c-Myc
axis. Some cancers display a competition between the repressive HIF-1α and activating c-Myc
transcription factors at the E-box of the promoter15. These two transcription factors seem to be
regulated through a multitude of pathways that are affected by arginine deprivation.
Mammalian target of rapamycin (mTOR) activity normally upregulates HIF-1α, repressing
ASS1, as shown in Figure 1.232. Because mTOR is a cellular nutrient sensor, its activity is
inhibited by the absence of certain amino acids, including arginine. This results in decreased
HIF-1α as ADI-PEG20 inhibits mTOR in ASS1-deficient cells (Figure 1.2). As HIF-1α levels
decrease, the Ras/ERK pathway and phosphoinositide 3-kinase (PI3K)/AKT/GSK-3β kinase
cascades are activated, resulting in an increase in c-Myc levels15,30. Specifically, ERK
phosphorylates c-Myc at S62, which is stabilizing33. Separately, AKT inhibits GSK-3ß from
phosphorylating c-Myc at T58, a site that promotes degradation33. The two pathways thereby
work together to stabilize c-Myc as it replaces HIF-1α on the ASS1 promoter. Our understanding
of how arginine starvation can be utilized with mTOR pathway modulation needs further
exploration.
Another possible mechanism of resistance can result from downregulation of
differentiated embryonic chondrocyte 1 (DEC1), another E-box-binding transcription factor, an
upstream regulator that promotes an increase in HIF-1α and decrease in c-Myc34. Silencing
7

DEC1 increased ASS1, lending support to the hypothesis that HIF-1α/c-Myc balance is the
dominant mechanism controlling ASS1 expression in many cells34. However, this study used
cells that lacked significant ASS1 promoter methylation in the untreated state, leaving open the
possibility that an unmethylated promoter is required for expression34. Performing a similar
study in cells that have been shown to silence ASS1 by promoter methylation would be
elucidating.
Arginine starvation can also lead to degradation of HIF-1α by way of the p300-HDAC2-Sin3A
chromatin remodeling system35. The histone acetyltransferase p300 normally maintains specific
histone acetylations that help to stabilize HIF-1α on the ASS1 promoter35. p300 dissociates upon
arginine starvation, and HDAC2 deacetylates these histones, allowing the formation of a HIF-1αproteasomal complex that leads to degradation35. Although other transcription factors such as
Sp4 and p53 are known to affect ASS1 transcription, there is no evidence that these factors
differentially affect ASS1 expression under arginine starvation10,15.
Upregulation of ASS1 takes time, and cells must sustain themselves in the meantime utilizing a
starvation pro-survival response1,2. For this, many ASS1-deficient cancers induce autophagy in
response to ADI-PEG201,13,36. This is caused largely by arginine deprivation inhibiting
mTORC1, which allows for increased autophagy. Autophagy, the process by which cells
consume parts of themselves, enables the recycling of intracellular arginine, which is
incorporated into proteins. This is a short-term response. By definition, autophagy is not
sustainable indefinitely as a sole source of nutrients. Cells must obtain outside resources to grow.
Therefore, autophagy can serve as a sort of bridge to ASS1 upregulation and long-term
resistance. However, a reliance on autophagy for any period of time presents a targetable
weakness in these cells that can be exploited by combining an autophagy inhibitor with ADI8

PEG20 in an attempt to kill cells before they can gain resistance. Indeed, multiple studies have
shown that the autophagy inhibitor chloroquine enhances the apoptotic effect of ADIPEG201,13,36. This combination may be more effective in an immune-competent system, as
autophagy-defective T cells show enhanced anti-tumor activity37.
Arginine deprivation also has major metabolic effects on arginine-auxotrophic cells which may
contribute to resistance. In one study, melanoma cell lines were found to increase their reliance
on both glycolysis and glutamine metabolism after becoming resistant to ADI-PEG203.
Supporting this conclusion about glutamine is a paper showing that ASS1-depleted cells rely less
on extracellular glutamine than ASS1-positive cells, which parallels the difference between cells
that are sensitive and resistant to arginine deprivation23. In addition to the increased reliance on
glycolysis in melanoma cells, another study shows a shift toward oxidative phosphorylation in
both melanoma and sarcoma cell lines2. This study once again finds an increased dependence on
glutamine metabolism in resistant cells2. Multiple melanoma and breast cancer cell lines have
been shown to become more resistant to glutamine deprivation as ASS1 expression increased in
the absence of arginine starvation, whereas loss of ASS1 sensitizes cells to combined arginine
and glutamine starvation38.
Many adaptive changes may be a consequence of increased c-Myc activity, which is necessary
for ASS1 upregulation, rather than adaptations to help the cell survive arginine starvation3. At
least one study has demonstrated significant cell death when glutaminase inhibition is combined
with ADI-PEG20, signifying that these cells may need glutamine in order to make more
glutamate and feed the tricarboxylic acid cycle2. The upregulation of c-Myc may also allow
therapeutic opportunities. Active, nuclear c-Myc is greatly increased by the combination of ADIPEG20 and docetaxel39. This in turn leads to increased human equilibrative nucleoside
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transporter 1 (hENT1) expression, which imports the nucleoside analog gemcitabine,
significantly enhancing its efficacy39.

1.3.2 Immunogenicity of ADI
Another important aspect of the response to arginine deprivation therapy occurs only in vivo.
Humans and other mammals mount a strong immune response to pure, recombinant ADI, as it is
a foreign bacterial enzyme. This results in a short circulating half-life, about 4 hours in mice, and
severely limits its effectiveness as a drug40. This is the main reason that the PEGylated version of
the drug was created. The polyethylene glycol cloaks the enzyme from recognition by the
immune system and greatly enhances its effectiveness in vivo28,41. However, many patients still
have immune responses to ADI-PEG20 over time42,43. Immune reactions are much slower to
occur than with pure ADI, but they can limit the time window in which ADI-PEG20 is effective.
Blood arginine levels commonly show a gradual increase after roughly 8 weeks of treatment,
which has been correlated to worse patient outcomes when used as a single agent42-44. However,
this window of effectiveness can be extended to at least 18 weeks by some combination
therapies, as has been shown recently in multiple clinical trials utilizing triple drug regimens that
include ADI-PEG2045,46. Correlated with this was a delayed buildup of anti-ADI-PEG20
antibodies42,44-46. These promising results should encourage further research to develop
combination therapies that kill quickly. Additionally, the immune adaptation period can likely be
harnessed for therapeutic purposes as tumors metabolically evolve in that time in vivo.
While the immune system can neutralize ADI-PEG20, the drug may also have a negative effect
on the immune system by depleting arginine. Low arginine levels are known to inhibit T cell
proliferation, as myeloid-derived suppressor cells do this naturally through the activity of
arginase I47. An arginase inhibitor therefore has potential to be effective in combination with
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ADI-PEG20 if anti-tumor T cells express ASS1 themselves and can make arginine. However,
this may inadvertently also provide tumor cells with arginine, possibly negating the immune
benefit. Arginine depletion has another detrimental effect on the anti-tumor activity of the
immune system, as ASS1 upregulation causes increased programmed death-ligand 1 (PD-L1)
expression, which is a negative regulator of T cells48,49. This suggests PD-1/PD-L1 immune
checkpoint blockade to be used in conjunction with ADI-PEG2048,49. There is even evidence that
ADI-PEG20 can enhance infiltration of T cells into tumors in mice, giving further support to the
potential of this combination49.
ASS1-deficient cells have also been found to have higher levels of cationic amino acid
transporter 1 (CAT-1), which is the most important arginine importer and a potential drug
target50,51. Furthermore, ASS1-deficient cells have been shown to increase import of arginine
through CAT-1 in response to ADI-PEG20 treatment51. The extent of the contribution of this
response to resistance was not determined, but it is likely mild and not enough to sustain growth,
since extracellular arginine levels remain extremely low.

1.3.3 Other Mechanisms of Resistance
ASS1 re-expression and autophagy have been discussed, but there are a plethora of other ways
for cells to obtain arginine, many of them unexplored as pathways for arginine deprivation
resistance. Here we summarize what is known about such pathways and their relevance to ADIPEG20 resistance. Macropinocytosis can be utilized by cancer cells to import and break down
extracellular proteins for any amino acid, including arginine52,53. A reliance on this pathway is
common in Ras-transformed cells and pancreatic cancers, but can also be used by other
cancers52,53. It is therefore possible that macropinocytosis may be an important resistance
pathway to arginine deprivation, as it has been shown to increase when mTORC1 is inhibited54.
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Similarly, many breast cancers can import necrotic cell debris in a process called necrocytosis55.
After three days of amino acid starvation, 35-71% of cellular protein biomass was found to
originate from necrocytosed peptides, and this process also provides carbohydrates, lipids, and
nucleotides55. Macropinocytosis and necrocytosis can also contribute significant amounts of
amino acids under normal growth conditions, suggesting that these pathways could immediately
provide relief from arginine starvation even without ASS1 upregulation52,53,55. There is also some
evidence that extracellular proteins, particularly albumin, can be taken up by receptor-mediated
endocytosis, although this process has not been shown to promote cell growth to the same extent
as macropinocytosis54,55.
Phagocytosis is another possible pathway to resistance, albeit unlikely, as only a few cell types
perform this activity. With this method, the cell would gain both cytoplasmic arginine and
protein-incorporated arginine from consumed cells, exosomes, or other material, along with all
other nutrients necessary for survival in the case of whole-cell phagocytosis. This phenomenon
has rarely been demonstrated in nonhematopoietic cells, but some breast cancer cell lines are
able to phagocytize yeast and extracellular matrix56,57. Some cancers can also perform a process
called entosis, whereby one cell invades another58. The internal cell can then either be released or
degraded by lysosomal enzymes, providing nutrients to the engulfing cell58. The end result
would be almost identical to phagocytosis with regards to nutrients. It is also conceivable that
slower-adapting cells are engulfed more often, which would hasten the onset of resistance in the
tumor overall.
Direct sharing of arginine from other cells through gap junctions (for example, immune cells and
fibroblasts in the stroma) also has not been ruled out. Heterologous gap junctions are presumably
rare but have been found between some cancer and non-cancer cells59,60. However, gap junctions
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are generally downregulated in cancer and therefore less likely to play a role in resistance61.
Alternatively, other cells in the body may supply arginine to ASS1-deficient cancer cells
indirectly. This mechanism has been shown with another amino acid, as mesenchymal cells in
the microenvironment where leukemic cells grow can produce and secrete asparagine, conferring
resistance to asparaginase treatment in some cases of acute lymphoblastic leukemia62.
The most effective form of resistance to arginine depletion is innate. Many cancers do not
downregulate ASS1 and are therefore immune to arginine deprivation therapy. Some apparently
ASS1-deficient cancers may also be heterogeneous in their expression. It would take only a
small number of highly expressing cells to eliminate the possibility of eradication through
arginine deprivation treatment. Even if the other cells all died, ASS1-high cells would be
clonally selected and grow out. This heterogeneity has not been a focus of research, but the field
would benefit from its investigation.

1.4 Current Clinical Trials
There have been many completed clinical trials involving ADI-PEG20, while others are
currently active or planned. These trials are summarized in Table 1.1. Numerous cancer types are
included across the trials, and many involve ADI-PEG20 monotherapy. However, some test
ADI-PEG20 in combination with other drugs, which is likely to be more effective for many
cancers that are not killed by monotherapy. There is great potential for similar combination trials
in the future, as ADI-PEG20 causes many potentially targetable adaptations in ASS1-deficient
cancers while having few side effects.
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1.5 Conclusions
Arginine auxotrophic cancers can be targeted by enzymes that degrade arginine in the blood.
However, many cancers gain resistance to the most widely used of these enzymes, ADI-PEG20,
by upregulating ASS1 and converting the degradation product citrulline back into arginine.
Before ASS1 levels are sufficiently increased for resistance, many cancers rely on autophagy to
temporarily recycle arginine and sustain themselves. There are also other possible mechanisms
by which cells could gain resistance. The most studied of these is macropinocytosis, with which
cells can ingest extracellular proteins to use as amino acids sources. Additionally, some parts of a
heterogeneous tumor may express higher levels of ASS1 than the rest and be resistant from the
start of treatment. Cells that are sensitive to arginine deprivation respond with numerous changes
in cellular metabolism and transcription factor activity, amongst other things. Many of these
changes can be targeted by other drugs in combination with ADI-PEG20. Exploration of the
multitude of metabolic adaptations to arginine deprivation has only just begun, and the future of
therapy development is bright.
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Figure 1.1. Urea and Citrulline-NO Cycles with Connections to Arginine Deprivation by
ADI-PEG20
Within the mitochondria, carbamoyl phosphate synthetase I (CPS1) incorporates ammonia into
carbamoyl phosphate. Ornithine transcarbamoylase (OTC) then condenses carbamoyl phosphate
with ornithine, forming citrulline. In the cytoplasm, argininosuccinate synthetase 1 (ASS1)
catalyzes the condensation of aspartate with citrulline to form argininosuccinate.
Argininosuccinate lyase (ASL) cleaves argininosuccinate into fumarate and arginine. Arginine is
hydrolyzed into ornithine and urea by arginase 1 (ARG1), completing the cycle. Alternatively,
nitric oxide synthase (NOS) can hydrolyze arginine to regenerate citrulline while producing
nitric oxide (NO). ADI-PEG20 degrades arginine to citrulline and ammonia extracellularly.
Citrulline can then be imported and converted to arginine by ASS1 and ASL.
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Figure 1.2. Common Pathway of Resistance to ADI-PEG20
Arginine deprivation caused by ADI-PEG20 inhibits mTORC1, resulting in a decrease of
repressive HIF-1α activity. By separate pathways, the positive transcription factor c-Myc is
upregulated and causes increased ASS1 transcription and translation. ADI-PEG20 treatment also
increases citrulline levels, which the cell can convert to arginine after ASS1 re-expression,
resulting in resistance and the ability to proliferate.
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NCT Number Conditions
NCT05001828 Acute Myeloid Leukemia, Adult
NCT04587830 Glioblastoma Multiforme (GBM)
NCT03254732 Advanced Solid Cancers
NCT02029690 Pleural Mesothelioma Malignant Advanced|
Peritoneal Mesothelioma Malignant Advanced|
Non-squamous Non-small Cell Lung Carcinoma|
Uveal Melanoma|Hepatocellular Carcinoma|
Glioma|Sarcomatoid Carcinoma
NCT05317819 Hepatocellular Carcinoma|
Advanced Hepatocellular Carcinoma
NCT02101580 Advanced Pancreatic Cancer
NCT01287585 Hepatocellular Carcinoma
NCT01948843 HER2 Negative Metastatic Breast Cancer
NCT01266018 Small Cell Lung Cancer
NCT03449901 Soft Tissue Sarcoma
NCT02101593 Hepatocellular Carcinoma
NCT01497925 Solid Tumors|Prostate Cancer
NCT01279967 Malignant Pleural Mesothelioma
NCT01910012 Acute Myeloid Leukemia
NCT02102022 Advanced Gastrointestinal (GI) Malignancies|
Hepatocellular Carcinoma|Gastric Cancer|
Colorectal Cancer
NCT02875093 Acute Myeloid Leukemia
NCT02709512 Mesothelioma
NCT01910025 Non-Hodgkin's Lymphoma
NCT01665183 Cutaneous Melanoma, Uveal Melanoma, Ovarian
Carcinoma or Other Advanced Solid Tumors
NCT03498222 Carcinoma, Non-Small-Cell Lung
NCT00520299 Metastatic Melanoma|Skin Cancer|Neoplasm
NCT04965714 Resectable Hepatocellular Carcinoma
NCT02006030 Unresectable Hepatocellular Carcinoma
NCT01528384 Argininosuccinate Synthetase Deficient
NCT03922880 Uveal Melanoma
NCT00056992 Carcinoma, Hepatocellular
NCT00450372 Melanoma (Skin)
NCT00029900 Melanoma|Neoplasm Metastasis

Drugs
ADI-PEG20
ADI-PEG20|Temozolomide
ADI-PEG20|Pembrolizumab
ADI-PEG20

Status
Not yet recruiting
Recruiting
Terminated
Terminated

ADI-PEG20

Recruiting

ADI-PEG20
ADI-PEG20
ADI-PEG20
ADI-PEG20
ADI-PEG20|Gemcitabine|Docetaxel
ADI-PEG20
ADI-PEG20
ADI-PEG20
ADI-PEG20
ADI-PEG20 plus modified FOLFOX6

Completed
Completed
Completed
Terminated
Active, not recruiting
Completed
Completed
Unknown status
Completed
Terminated

ADI-PEG20|Cytarabine
ADI-PEG20 plus Pem Cis
ADI-PEG20
ADI-PEG20

Terminated
Active, not recruiting
Completed
Completed

Atezolizumab|Pemetrexed|
Carboplatin|ADI-PEG20
ADI-PEG20
Nivolumab|ADI-PEG20
ADI-PEG20
ADI-PEG20
ADI-PEG20|Nivolumab|Ipilimumab
ADI-PEG20
ADI-PEG20
ADI-PEG20

Withdrawn

Table 1.1. List of All Clinical Trials of ADI-PEG20

17

Completed
Recruiting
Completed
Completed
Active, not recruiting
Completed
Completed
Completed
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Chapter 2: Intracellular Arginine-Dependent
Translation Sensor Reveals the Dynamics of
Arginine Starvation Response and Resistance
in ASS1-Negative Cells
This chapter is based on the publication listed below and has been reformatted to adhere to
dissertation guidelines.
Rogers, L. C. et al. Intracellular arginine-dependent translation sensor reveals the dynamics of
arginine starvation response and resistance in ASS1-negative cells. Cancer Metabolism 9, 4
(2021) doi:10.1186/s40170-021-00238-9.
Contributing authors are Leonard Rogers, Jing Zhou, Adriana Baker, Charles Schutt, Prashanta
Panda, and Brian Van Tine.

2.1 Abstract
2.1.1 Background
Many cancers silence the metabolic enzyme argininosuccinate synthetase 1 (ASS1), the ratelimiting enzyme for arginine biosynthesis within the urea cycle. Consequently, ASS1-negative
cells are susceptible to depletion of extracellular arginine by PEGylated arginine deiminase
(ADI-PEG20), an agent currently being developed in clinical trials. As the primary mechanism
of resistance to arginine depletion is re-expression of ASS1, we sought a tool to understand the
temporal emergence of the resistance phenotype at the single cell level.
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2.1.2 Methods
A real-time, single-cell florescence biosensor was developed to monitor arginine-dependent
protein translation. The versatile, protein-based sensor provides temporal information about the
metabolic adaptation of cells, as it is able to quantify and track individual cells over time.

2.1.3 Results
Every ASS1-deficient cell analyzed was found to respond to arginine deprivation by decreased
expression of the sensor, indicating an absence of resistance in the naïve cell population.
However, the temporal recovery and emergence of resistance varied widely amongst cells,
suggesting a heterogeneous metabolic response. The sensor also enabled determination of a
minimal arginine concentration required for its optimal translation.

2.1.4 Conclusions
The translation-dependent sensor developed here is able to accurately track the development of
resistance in ASS1-deficient cells treated with ADI-PEG20. Its ability to track single cells over
time allowed the determination that resistance is not present in the naïve population, as well as
elucidating the heterogeneity of the timing and extent of resistance. This tool represents a useful
advance in the study of arginine deprivation, while its design has potential to be adapted to other
amino acids.

2.2 Background
Arginine is acquired either extracellularly from the blood stream or synthesized intracellularly by
enzymes from the urea cycle. The rate limiting step in arginine biosynthesis is catalyzed by
argininosuccinate synthetase 1 (ASS1) (EC 6.3.4.5)1. As most arginine is made and exported
from kidney cells for utilization by other cell types, many cancers take advantage of this
extracellular supply by silencing ASS1 expression without compromising their arginine supply225
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. Cancer is thought to silence ASS1 to free aspartate pools for the biosynthesis that is associated

with rapid cell division7.
ASS1-deficient cells must import extracellular arginine to survive and grow, making arginine
depletion an attractive therapeutic strategy. Therefore, multiple arginine-depleting enzymes have
been developed. The most clinically tested of these is arginine deiminase conjugated to
polyethylene glycol, ADI-PEG205,8. This enzyme functions extracellularly to break down
arginine into citrulline and ammonia9. Most cells in the body are not greatly affected, as their
ASS1 expression levels are sufficient for arginine production and/or their metabolic
requirements for arginine are much lower than rapidly proliferating cells.
There are multiple possible mechanisms of resistance to arginine starvation, but the most
common mechanism is the re-expression of ASS15,10-12. This is because the gene remains
unaltered at the sequence level in most ASS1-deficient cells, as it is silenced by methylation13,14.
Mechanistically, when arginine is depleted by ADI-PEG20, c-Myc is activated and translocates
to the nucleus, where it binds to the ASS1 promoter and upregulates transcription, leading to
intracellular arginine production10,11,15,16. The timing and heterogeneity of the emergence of
resistance are important to understand for clinical translation, but until now, tools have been
lacking to effectively study arginine metabolism at the single-cell level.
Many methods have been developed to measure biological arginine concentrations17. While these
assays can be useful, they are often expensive and difficult to use, and most are aimed toward
food and medical systems17. Very few of the available methods measure intracellular
concentrations in live cells, and most of these do not allow for real-time measurements17. The
only published dynamic intracellular sensor of arginine in mammalian cells relies on an arginine26

binding protein from Chlamydia pneumoniae18. Unfortunately, this system is not suitable for
studying biologically relevant arginine concentrations, as it responds only to arginine
concentrations that are higher than physiologic arginine levels18.
Most organisms also have mechanisms for sensing amino acid concentrations. In higher
organisms, the mTOR pathway senses nutrients, including arginine19-21, and is tied to cell
proliferation22. In bacteria, trp operon attenuation utilizes a potentially useful mechanism. As the
operon is transcribed, a ribosome translates the nascent mRNA, following closely behind the
RNA polymerase. When tryptophan is abundant, the ribosome proceeds along the mRNA,
allowing a transcription termination signal to form in the mRNA and halt transcription23. When
tryptophan is scarce, the ribosome stalls, an alternate mRNA structure forms, and transcription
continues23. Such ribosomal stalling during amino acid scarcity has been demonstrated in human
cells specifically in response to arginine deprivation24.
This study characterizes and describes the development of an arginine translation sensor
(ArgSen) based on the principle of ribosomal stalling. Several different structural components
proved useful in studying cellular responses to arginine deprivation, as they were combined to
create a novel chimeric protein that would need to satisfy multiple criteria. The ArgSen monitors
cellular arginine-dependent translation in individual cells and entire populations over time
without adversely affecting growth or response to stimuli. We demonstrate that when ASS1deficient cells are treated with ADI-PEG20, there is a homogeneous decrease in translational
capacity, but a heterogeneous pattern of resistance. Finally, we calculate the minimum
concentration of arginine needed for optimal sensor translation.
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2.3 Methods
2.3.1 Cell Culture
SKLMS1, SKUT1, and SKMEL2 cell lines were obtained from American Type Culture
Collection (Manassas, VA) and are listed in Supplemental Table S2.1. WT cancer cell lines were
grown in MEM (Thermo Fisher Scientific, Waltham, MA) supplemented with 10% FBS (BioTechne, Minneapolis, MN), 1.3% 100X penicillin-streptomycin (10,000U/mL) (Thermo Fisher
Scientific), and 2.5 µg/mL Plasmocin (InvivoGen, San Diego, CA). LTAT cells were grown in
this medium with 1 µg/mL ADI-PEG20 (Polaris, San Diego, CA) added. All ADI-PEG20
treatments were performed by replacing media with media that had been pre-treated with 1
µg/mL ADI-PEG20 for at least 8 hours at 37° C.
Mouse embryonic fibroblasts (MEFs) were generated as detailed later. MEFs were grown in
IMDM (Thermo Fisher Scientific) supplemented with 20% FBS, 1% 100X MEM non-essential
amino acids (Thermo Fisher Scientific), 0.0007% 2-mercaptoethanol (MilliporeSigma,
Burlington, MA), 1% 100X penicillin-streptomycin (10,000U/mL), and 2.5 µg/mL Plasmocin.

2.3.2 Automated Cell Imaging
Cells were transduced with Incucyte® Nuclight Red Lentivirus Reagent (Essen BioScience, Ann
Arbor, MI) and selected with puromycin. SKLMS1, SKUT1, and SKMEL2 cells were plated in
96-well plates at 3X103, 7.5X103, and 5X103 cells per well, respectively. The next day, fresh
phenol red-free medium was added to start treatment along with 50 nM YOYO™-1 Iodide
(Thermo Fisher Scientific), which fluoresces green within the nuclei of dead cells. Images were
taken with Incucyte® ZOOM or Incucyte® S3 (Essen BioScience) automated fluorescent
microscopes at a rate of 0.5-1 per hour. Red and green cell numbers were quantified
automatically with an analysis algorithm within the Incucyte software (Essen BioScience).
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SKLMS1, SKUT1, and SKMEL2 cells expressing the indicated GFP arginine sensor variants
were plated in 96-well plates at 3X103, 7.5X103, and 5X103 cells per well, respectively. The next
day, fresh phenol red-free medium was added to start treatment. Glutamine deprivation
experiments used media supplemented with One Shot™ dialyzed FBS (Thermo Fisher
Scientific) in place of standard FBS, and 2 mM L-Glutamine (Corning, Corning, NY) was either
added or omitted. Images were taken with Incucyte® ZOOM or Incucyte® S3 automated
fluorescent microscopes at a rate of 0.5-1 per hour. Sensor fluorescence was quantified
automatically with an analysis algorithm within the Incucyte software, and average integrated
intensities of green fluorescence in individual cells were taken.
SILAC RPMI 1640 Flex Media, with no glucose and no phenol red (Thermo Fisher Scientific)
was used in experiments to vary arginine concentrations. Glucose (Agilent Technologies, Santa
Clara, CA), L-glutamine, and L-lysine hydrochloride (MilliporeSigma) were added to the same
concentrations as in RPMI 1640 (Thermo Fisher Scientific), along with 10% dialyzed FBS and
1.3% pen/strep. L-arginine (MilliporeSigma) was added to the indicated concentrations. Cells
were grown and passaged in RPMI 1640 for at least one week before arginine concentration
experiments. Fluorescence of the arginine sensor was measured with the Incucyte S3 at 0, 1, and
2 hours of the indicated treatments. The areas under the curve for this time period were then
plotted against arginine concentration, with 0 represented as 0.01 µM. Data were fit to the
following equation:

𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +

(𝑋 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 )×(𝑇𝑜𝑝−𝐵𝑜𝑡𝑡𝑜𝑚)
(𝑋 𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 + 𝐸𝐶50𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒 )

(2.1)

Effective concentration (EC) of any other value (F) was then calculated with the following
equation:
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𝐹

√𝐻𝑖𝑙𝑙𝑆𝑙𝑜𝑝𝑒

𝐸𝐶𝐹 = (100−𝐹)

× 𝐸𝐶50

(2.2)

Where indicated, 100 µM cycloheximide (CHX) (MilliporeSigma) or 1 µM bortezomib (BTZ)
(Millennium Pharmaceuticals, Cambridge, MA) was added to media. Fluorescence data in the
presence of CHX were fit to the following exponential one-phase decay equation:
𝑌 = (𝑌0 − 𝑃𝑙𝑎𝑡𝑒𝑎𝑢) ∗ 𝑒 −𝐾∗𝑋 + 𝑃𝑙𝑎𝑡𝑒𝑎𝑢 (2.3)
Half-lives were calculated as (ln(2)/K).

2.3.3 Individual Cell Tracking
Arginine sensor fluorescence of individual cells was tracked over time by hand within the
Incucyte S3 software by recording the integrated intensity of green objects (nuclei) detected by
the analysis algorithm. 100 cells were initially targeted for tracking in each experimental
condition. Results include data from less than 100 cells, as not all cells were able to be tracked
with certainty. At timepoints where fluorescence in a cell was too low to be detected by the
algorithm, the integrated intensity value was recorded as 0.

2.3.4 Capillary Electrophoresis
For obtaining lysates after a time course of ADI-PEG20, SKLMS1 cells were plated in 60-mm
dishes, and treatments were administered so that all ended simultaneously. 7.5X104 LTAT cells
were plated for every timepoint. 7.5X104 WT cells were plated for samples with 12 or fewer
hours of treatment, and the number was doubled for each full day of treatment, with 6X105 cells
plated for 72 hours. Treatment was started by the addition of fresh media the next day. All
samples received fresh media 2 hours before harvesting. After lysis, immunoblots were
performed with a Wes automated immunoblot machine (Bio-Techne) according to the
manufacturer’s protocol25. Each sample was normalized to its own total protein25. Two ASS1
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primary antibodies were used: a non-commercial mouse monoclonal from Polaris and a rabbit
polyclonal ab175607 (Abcam, Cambridge, MA). Mouse monoclonal GFP antibody sc-9996
(Santa Cruz Biotechnology, Dallas, TX) was used to detect the arginine sensor. Two bands were
detected at approximately the expected molecular size of the GFP sensor, and both were
quantified and added together before normalization to total protein. Although a single band was
expected, the identity of the two separate bands was not investigated. Antibodies are listed in
Supplemental Table S2.2.

2.3.5 Cloning
A gBlocks® Gene Fragment (Integrated DNA Technologies, Coralville, IA) of the first arginine
sensor variant (ArgSen (-) NLS), containing a P2A site and Fast-FT without a nuclear
localization sequence (NLS), was cloned using AscI and NotI restriction sites. All gBlocks® in
this study were ordered with extra nucleotides on each end to allow for direct restriction
digestion and ligation into the vector. All arginine sensor variations were first cloned into
plasmid pKLV2-EF1a-BsdCas9-W (replacing the original insert), then subcloned into plasmid
pLV-EF1a-IRES-Puro. pKLV2-EF1a-BsdCas9-W was a gift from Kosuke Yusa (Addgene
plasmid #67978; http://n2t.net/addgene:67978; RRID:Addgene_67978)26. pLV-EF1a-IRES-Puro
was a gift from Tobias Meyer (Addgene plasmid #85132; http://n2t.net/addgene:85132;
RRID:Addgene_85132)27. Successful cloning was confirmed by Sanger sequencing with primers
EF1a fwd, pKLV2 seq rev, pLV seq rev, and Rad23b end fwd. All oligonucleotides in this study
were ordered from Integrated DNA Technologies and are listed in Supplemental Table S2.3.
After cloning ArgSen (-) NLS, multiple modifications were made. A C-terminal SV40 Large Tantigen NLS was added by amplification of Fast-FT with SalI BamHI FastFT fwd and NotI NLS
FastFT rev primers, followed by replacement of Fast-FT with Fast-FT-NLS using BamHI and
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NotI restriction sites (ArgSen). Separately, the P2A site was removed by SalI restriction
digestion followed by ligation (Argsen (-)P2A (-)NLS). Fast-FT in ArgSen (-)P2A (-)NLS was
then replaced by enhanced green fluorescent protein with a C-terminal NLS (GFP-NLS) that had
been PCR amplified with SalI BamHI GFP fwd and NotI NLS GFP rev primers, using BamHI
and NotI restriction sites (GFP ArgSen). The polyarginine region in this variant was then
replaced with a region of identical length encoding random non-arginine amino acids, obtained
as a gBlock® and cloned with restriction sites XbaI and EcoRI (GFP RanSen).
Variations of the sensor with regions deleted to test degradation were derived from GFP ArgSen.
DNA oligonucleotide pairs designed to replace targeted regions with short linkers were
phosphorylated on their 5’ ends by T4 Polynucleotide Kinase (New England Biolabs, Ipswich,
MA), then annealed. After annealing, each double-stranded oligonucleotide possessed
complementary overhangs with the correct sequences to bind to the digested restriction sites on
either side of its target region. The target region was cut out of the vector at these sites, and the
newly annealed oligonucleotide was ligated in. NucGFP was made with Reporter only
oligonucleotides using AscI and BamHI restriction sites. Δ Degradation Domain was made with
Proteasomal del oligonucleotides using AscI and BstBI restriction sites. Δ Disordered Region
was made with Disordered del oligonucleotides using AscI and NsiI restriction sites. Δ Rad23b
UbL was made with Rad23b del oligonucleotides using NsiI and XbaI restriction sites. After
publication, all constructs will be available from Addgene (Watertown, MA).
Lentiviral particles were made with Lenti-X™ 293T cells (Takara Bio USA, Mountain View,
CA). Experimental cells were transduced with virus and selected with puromycin.
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2.3.6 Flow Cytometry
SKLMS1 ArgSen cells were plated in 6-well plates for a time course of ADI-PEG20, along with
control WT cells for each timepoint. To enable simultaneous harvesting at similar levels of
confluency, the following numbers of cells were plated per well according to the length of ADIPEG20 treatment: 1X105 for 72 hours, 6.5X104 for 48 hours, 4X104 for 24 and 18 hours, and
2.5X104 for 12 or fewer hours. All samples received fresh media 2 hours before harvesting. Cells
were washed with PBS, harvested with trypsin, and measured for fluorescence of blue Fast-FT
by flow cytometry with a 407 nm laser and 50 nm wide bandpass filter centered at 450 nm.
Fluorescence values of paired WT samples were subtracted from ArgSen samples, and values
were then normalized to untreated fluorescence levels.

2.3.7 RT-qPCR
For isolating RNA after a time course of ADI-PEG20 treatment, SKLMS1 cells were plated in
60-mm dishes, and treatments were administered so that all ended simultaneously. 7.5X104 cells
were plated for samples with 12 or fewer hours of treatment, and double for each full day of
treatment, with 6X105 cells plated for 72 hours. All samples received fresh media 2 hours before
harvesting. Cells were washed in ice-cold PBS, scraped, and centrifuged. RNA was isolated by
Direct-zol™ RNA Miniprep Plus kit (Zymo Research, Irvine, CA) according to the
manufacturer’s protocol. The High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) was used to produce cDNA according to the manufacturer’s protocol. The
Power SYBR™ Green PCR Master Mix (Thermo Fisher Scientific) was then used to quantify
arginine sensor and GAPDH mRNA according to the manufacturer’s protocol. qrtPCR ArgSen
fwd, qrtPCR ArgSen rev, qrtPCR GAPDH fwd, and qrtPCR GAPDH rev primers were used in
the RT-qPCR reactions.
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2.3.8 Protein Translation Assay
SKLMS1 WT cells were plated at 6X103 cells per well in a 96-well plate. The next day, media
was replaced and indicated treatments were given at indicated times so that the assay began
simultaneously for all samples. The Click-&-Go Plus 647 OPP Protein Synthesis Assay Kit
(Click Chemistry Tools, Scottsdale, AZ) was used according to manufacturer’s instructions. Red
fluorescence was measured on the Incucyte S3, and cell-by-cell analysis was performed to
quantify the mean intensity of fluorescence in each cell. The average fluorescences of CHX
controls for each timepoint were subtracted from each sample before normalization to the
untreated 0 timepoint.

2.3.9 Mouse Embryonic Fibroblast Generation
HEPD0731_5_F08 mutant embryonic stem cell clones were ordered from the European
Conditional Mouse Mutagenesis Program (EUCOMM). These cells contain an allele of ASS1
harboring FRT-flanked lacZ and neomycin resistance genes, followed by a loxP site upstream of
critical exon 4 and another loxP site downstream of exon 4. Embryos were grown from these
stem cells, and the resulting mice were crossed with mice expressing FLP recombinase. This
cross removed the cassette containing lacZ and neomycin resistance genes, allowing the ASS1
allele to encode functional ASS1 protein. These mice were then backcrossed to C57BL/6 mice
with confirmed FLP-negative genotypes three times to remove FLP and possess ASS1F/+ alleles.
ASS1F/+ mice were crossed to each other, and a colony of ASS1F/F mice was established.
MEFs were generated from embryos harvested from an ASS1F/F X ASS1F/F mating. MEFs were
allowed to grow normally and became spontaneously immortalized. MEFs were infected with
either Ad5CMVCre or Ad5CMVcytoLacZ adenoviral particles (University of Iowa, Iowa City,
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IA) to knock out ASS1 or serve as a negative control, respectively. Complete knockout of ASS1
was confirmed by both genotyping and immunoblot.

2.3.10 Metabolomics
For metabolomic analysis, SKLMS1 WT and LTAT cells expressing GFP ArgSen were plated in
replicates of four on 100 mm dishes at 2X106 cells per dish for every condition except LTAT
with 48 hours of ADI-PEG20, which had 1X106 cells. The next day, cells were treated with ADIPEG20 for the indicated time periods, with each sample getting fresh media one hour before
harvesting. Viable cells were counted for one sample from each condition, to be used for
normalization. Metabolites were extracted from the remaining three samples with methanol using
the protocol for extraction of metabolites from adherent cells from Human Metabolome
Technologies America (HMT) (Boston, MA). Purified metabolites and viable cell counts were
then sent to HMT for metabolomic analysis. Data from HMT were then normalized to ratios of
individual sample total metabolites to average total metabolite levels per 1X106 cells. The
concentrations of arginine in ADI-PEG20-treated MEM and untreated MEM were also
determined by HMT.

2.3.11 Cell Volume Determination
For determining cell volume after 48 hours of ADI-PEG20 treatment, cells were plated and
treated identically to the metabolomics experiment, then harvested by trypsin. Samples were
mixed well, and 20 µL of each were taken, mixed with an equal volume of trypan blue (Thermo
Fisher Scientific), pipetted into Countess™ Cell Counting Chamber Slides (Thermo Fisher
Scientific), and analyzed by a Countess™ II Automated Cell Counter (Thermo Fisher Scientific).
Average cell diameter was calculated from this data. The remaining cells were analyzed by flow
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cytometry, measuring forward scatter intensity to determine relative cell diameters. Individual
and average cell volumes were then calculated with FlowJo software (FlowJo, Ashland, OR).

2.3.12 Statistics
Data were analyzed using GraphPad Prism 8 Software (GraphPad Software, San Diego, CA).
mRNA and GFP immunoblot error bars represent standard error of the mean. All other error bars
represent standard deviation. ASS1 protein expression differences were analyzed by unpaired t
test. Growth rate differences were analyzed by one-way ANOVA. Metabolite differences at 48
hours were analyzed by Welch’s t test. “ns” denotes non-significant difference between groups. *
denotes p < .05, ** denotes p < .01, *** denotes p < .001, and **** denotes p < .0001.

2.4 Results
2.4.1 Resistance to ADI-PEG20
The established working model of resistance to arginine starvation is demonstrated in Figure
2.1a10-12. In ASS1-deficient cells, arginine is imported from the extracellular space. Upon the
addition of ADI-PEG20, extracellular arginine is converted to citrulline, which causes a cellular
starvation state that induces a c-Myc-dependent re-expression of ASS110-12. This is the primary
mechanism of arginine starvation resistance, as re-expression of ASS1 allows the intracellular
production of arginine through urea cycle enzymes. As more ASS1 is expressed, the cell can
synthesize more arginine from citrulline, thus allowing cells to grow in the absence of
extracellular arginine. ASS1-deficient cells moderately increase expression of ASS1 in the short
term in response to arginine deprivation, but in the long term, ASS1 is greatly upregulated
(Figure 2.1b)10-12.
To model the response of cells to the arginine starvation state, two well-characterized human
sarcoma cell lines, SKLMS1 and SKUT1, and one human melanoma cell line, SKMEL2, were
36

used12,16,28. As these lines express very little ASS1 at baseline, long term ADI-PEG20 treatment
(LTAT) resistant cell lines were derived as previously described by Kremer et al.12. The longer
the cell lines were cultured with ADI-PEG20, the more ASS1 protein was expressed (Figure
2.1b). Next, we confirmed that arginine starvation in ASS1-negative cell lines leads to a
cytostatic response, as all three WT cell lines demonstrated significantly decreased cellular
proliferation when monitored by Incucyte Nuclight Red counts over 72 hours, whereas LTAT
cells grew at a similar rate as untreated WT cells (Figure 2.1c). Finally, we demonstrated that
cell death is not meaningfully increased in the arginine starvation state (Figure 2.1d).

2.4.2 Arginine Sensor Design
To gain a better understanding of the temporal emergence of resistance to ADI-PEG20 in real
time, a florescence-based protein sensor was designed to measure arginine-dependent protein
translation. A lentiviral delivery system is utilized to integrate the sensor gene into the host
genome. The EF1α promoter was chosen to mimic endogenous arginine-dependent translation,
as this drives homogeneous and stable transcription in human cells29. In addition, seven
components were incorporated into the sensor (Figure 2.2a). A fluorescent timer protein was
used to optimize the first-generation reporter (ArgSen), as classical fluorescent proteins do not
degrade fast enough for their fluorescence to noticeably decrease within a few hours of stopping
translation. Fast-FT was chosen, as it matures from blue to red over a few hours in the cell,
allowing only recently translated proteins to be measured by blue fluorescence30. However, most
experiments were performed with an enhanced green fluorescent protein version of the sensor
(GFP ArgSen), made possible by attaching a domain that rapidly degrades the GFP. Finally, a
nuclear localization signal was added to enable better quantification via microscopy.
The core part of the arginine sensor is a polyarginine region that enables a more specific
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response to intracellular arginine levels (Figure 2.2a). When the cell is starved of arginine with
ADI-PEG20, this region should be translated more slowly, causing ribosomal pausing and/or
stalling24, resulting in slower translation of the downstream reporter protein. 20 arginine residues
are included in this region.
Upstream of and attached to the polyarginine motif is a strong proteasomal degradation signal
(Figure 2.2a), allowing the arginines to be recycled quickly, as the incorporated arginine
residues might deplete cytoplasmic levels of the amino acid in the cell. The degradation domain
also causes rapid depletion of the reporter when translation rates decrease, which is critical for
the temporal sensitivity of the sensor. The degradation domain consists of three parts, Rad23b
ubiquitin-like domain (UbL), the N terminus of human thymidylate synthase (hTS), and a
disordered region. To promote ubiquitin-independent proteasomal degradation, a human Rad23b
UbL domain was added. This domain has been shown to localize attached proteins to the
proteasome and facilitate their rapid degradation31. hTS is degraded in a manner totally
independent of ubiquitin32. The 30 amino acids from the N terminus of hTS are essential for its
degradation and were therefore chosen as the N terminus of the sensor32. The hTS N terminus is
short, but studies have shown that longer disordered regions generally lead to faster proteasomal
degradation33,34. For this reason, a long, disordered region was included. The measles virus
phosphoprotein C-terminal domain flexible disordered linker was chosen as the long disordered
region from a data set used to validate the Multilayered Fusion-based Disorder predictor v. 2.00
(MFDp2)35-37. Additional groups have confirmed that this region is a natural long, disordered
linker38-40.
Due to the intrinsic ability of Fast-FT to signal only recently translated proteins by blue
fluorescence, a P2A site was included after the polyarginine motif and before the Fast-FT in this
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first version of the sensor. The P2A essentially acts as a self-cleavage site, and its inclusion is an
effective way to translate two polypeptides from the same mRNA in the same quantity41, which
frees Fast-FT to function independently while recycling the upstream arginine (Figure 2.2a). The
GFP ArgSen, standardly used for most of the studies, does not include the P2A site, causing the
GFP to be degraded quickly.

2.4.3 Sensor Response to ADI-PEG20
Flow cytometric analysis was performed on SKLMS1 cells expressing the Fast-FT arginine
sensor (ArgSen) to characterize its fluorescence over time when cells were treated with ADIPEG20 to deplete extracellular arginine. Flow cytometric analysis shows a decrease of ArgSen
fluorescence with a minimum signal seen at 12 hours, followed by a recovery of fluorescence
back to untreated levels by 72 hours (Figure 2.2b), which is consistent with re-expression of
ASS1 (Figure 2.1b) and the reinitiation of proliferation (Figure 2.1c). After transducing cells
with GFP ArgSen, the response to ADI-PEG20 was compared to a variant in which the arginine
residues of the polyarginine motif were replaced with random non-arginine amino acid residues
(GFP RanSen) (Figure 2.2c). This decreased the overall arginine content in the protein from 37
in GFP ArgSen to 17 residues in GFP RanSen, and the response to ADI-PEG20 was reduced
correspondingly (Figure 2.2c). GFP ArgSen mRNA levels do not decrease with ADI-PEG20
treatment, staying relatively steady for 48 hours, with some increase but no decrease in
transcription seen after that time, suggesting that this is a translational and not transcriptional
probe for arginine starvation response (Figure 2.2d).
Without treatment, sensor expression gradually decreases over time as cells grow, deplete
nutrients, and become more confluent (Figure 2.2e). In WT cells treated with ADI-PEG20,
sensor fluorescence is reduced initially, then recovers over time, whereas untreated and LTAT
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cells maintain relatively steady fluorescence (Figure 2.2e). Some cell lines, such as SKLMS1,
are dependent on glutamine and therefore grow slowly in response to glutamine deprivation28. In
response to glutamine withdrawal, SKLMS1 cells reduce GFP ArgSen signal overtime, but with
slower kinetics than ADI-PEG20 treatment, and SKUT1 and SKMEL2 respond similarly (Figure
2.2e). This is consistent with the sensor also responding to general protein translation. Glutamine
deprivation has less effect on global translation rates than ADI-PEG20 in SKLMS1 (shown in
Supplemental Figure S2.1), but Figures 2.2c and 2.2e taken together indicate that GFP ArgSen
expression is preferentially affected by arginine availability over other amino acids.
Cells were then treated with ADI-PEG20 for 12 hours, near the minimum point of GFP ArgSen
fluorescence, and then placed in normal growth media (Figure 2.2f). GFP ArgSen fluorescence
increased rapidly over the few hours following addition of complete media, stabilizing at roughly
the baseline level, then slowly decreasing at a similar rate as untreated cells.
To test whether ASS1 expression is required for ADI-PEG20 resistance, GFP ArgSen was
expressed in MEFs with ASS1 either knocked out (ASS1-/-) or expressed at normal levels
(ASS1F/F). When treated with ADI-PEG20, ASS1F/F MEFs experienced a moderate decrease in
fluorescence followed by recovery, whereas fluorescence decreased more rapidly and did not
recover in ASS1-/- MEFs (shown in Supplemental Figure S2.2). ADI-PEG20 also completely
stopped the growth of ASS1-/- MEFs but not ASS1F/F MEFs (shown in Supplemental Figure S2.2).

2.4.4 Sensor Component Characterization
Degradation and recycling of the sensor probe’s arginines are important for temporal resolution
and to avoid unwanted arginine depletion. The GFP ArgSen is in a constant state of balance
between rapid synthesis and rapid degradation, resulting in a relatively low steady state level of
GFP due to the incorporation of its rapid degradation domain. Any disturbance of either
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translation or degradation, such as ADI-PEG20 treatment or translation or proteasome inhibitors,
should affect the levels of GFP in the cell. With this design, faster degradation gives better
temporal resolution to the sensor. For this reason, we characterized the importance of each
upstream (of reporter) sensor component to the efficiency of degradation. GFP ArgSen
degradation was measured in the presence of the translation inhibitor cycloheximide (CHX), and
this was compared to variants with deletions of various regions upstream of the GFP (Figure
2.3a). The complete sensor (GFP ArgSen) was found to degrade the fastest, as measured by its
half-life of approximately 2.7 hours (Figure 2.3b). However, deletion of either the designed
disordered region or the ubiquitin-like domain led to only a slight increase in half-life of less
than 1 hour (Figure 2.3b). All variants that included the polyarginine motif degraded much faster
than nuclear GFP alone (labeled NucGFP; >100 hours half-life), including the variant with no
degradation domain (Figure 2.3b).
ADI-PEG20 causes a similar but slower decline in sensor fluorescence when compared to CHX
(Figure 2.3c). Images show that translation inhibitor CHX rapidly depletes sensor fluorescence in
cells, while proteasomal inhibitor bortezomib (BTZ) temporarily increases fluorescence before
cell death (Figure 2.3c). To test whether translation and proteasomal degradation of the sensor
continue even after arginine depletion, SKLMS1 WT cells were treated with CHX at multiple
time points after starting ADI-PEG20 treatment. Results demonstrated the expected pattern of a
rapid decrease in fluorescence, indicating that proteasomal degradation is not significantly
affected by ADI-PEG20 (Figure 2.3d). Next, cells were treated with BTZ at 0 or 48 hours after
ADI-PEG20 treatment. BTZ treatment at either time point resulted in higher sensor fluorescence
in the following hours compared to control (Figure 2.3e).
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To correlate sensor fluorescence with protein expression by an independent method,
immunoblots by capillary electrophoresis for arginine sensor reporter protein were performed
over a time course of ADI-PEG20 in SKLMS1 WT, showing a similar kinetic pattern as flow
cytometry and microscopy measurements (Figures 2.3f and 2.3g). The pattern of sensor
expression is also relatively unchanged when normalized to mRNA levels, with the exception of
a moderate decrease at 72 hours due to increased mRNA at that time (Figure 2.3g).

2.4.5 Single Cell Tracking
To determine the dynamics of cellular responses to arginine deprivation, integrated green
fluorescence intensities of individual WT cells were tracked over time with and without arginine
depletion by ADI-PEG20. In the absence of arginine depletion, the majority of cells increased or
maintained relatively steady sensor fluorescence before undergoing mitosis (Figure 2.4a). With
ADI-PEG20 treatment, every measured cell decreased expression of the sensor before some cells
recovered expression over time (Figure 2.4a). The timing of recovery varied among cells, and the
magnitude varied even more, indicating heterogeneous resistance (Figure 2.4a). Higher
proportions of cells in Figure 2.4a die with ADI-PEG20 treatment than are shown in Figure 2.1d.
This is because Figure 2.4a does not include daughter cells from divisions, which increase the
total live cell numbers by 72 hours.
SKLMS1, SKUT1, and SKMEL2 WT cells with and without ADI-PEG20 over time were
imaged with the Incucyte S3 (Figure 2.4b). Representative images at 4, 24, and 72 hours are
shown. At 4 and 24 hours, most treated cells have significantly decreased fluorescence compared
to their untreated controls. This fluorescence is recovered in some treated cells at 72 hours, while
untreated cells have become confluent, causing downregulation of translation, especially in
SKLMS1 and SKMEL2.
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We then determined the percentage of cells that had divided, died or neither (labeled as
“analyzed”) at both 4 and 24 hours, shown in Figure 2.4c. In each cell line at both time points, a
significantly lower percentage of cells treated with ADI-PEG20 had divided, supporting the
growth data in Figure 2.1c. The cells which neither divided nor died through each time point
were then categorized according to their change in arginine sensor fluorescence. At 4 hours, no
treated cells had increased expression of the sensor, while over 83% of untreated cells in each
cell line had increased expression or had not changed. At 24 hours, fluorescence remained low in
90-96% of treated cells, while the remaining subset had already started to recover (Figures 2.4a
and 2.4c). Less than 7% of untreated cells in any cell line neither divided nor died by 24 hours,
limiting the usefulness of categorizing. A subset of cells that divided and their descendants were
able to be tracked, but most descendants were lost due to confluent crowding and imaging
limitations of the Incucyte S3. Those descendants that could be tracked with confidence showed
a very similar pattern of sensor fluorescence as cells that did not divide within 72 hours (shown
in Supplemental Figure S2.3).

2.4.6 Metabolic Analysis
Metabolomic analysis by mass spectrometry of SKLMS1 WT and LTAT cells treated with ADIPEG20 over time demonstrates a decrease in intracellular arginine concentration that occurs
within 1 hour (Figure 2.5a). Arginine levels do not recover within 48 hours (Figure 2.5a).
However, the steady state intracellular arginine levels are roughly five times higher in LTAT
cells than in WT cells when treated with ADI-PEG20 (Figure 2.5a). As expected, intracellular
citrulline levels start low and increase greatly over time (Figure 2.5b). Maximum citrulline levels
are not reached by 12 hours, and citrulline levels stay significantly lower in LTAT cells than in
WT cells (Figure 2.5b), as expected in cells with a functional amount of ASS1.
43

2.4.7 Minimum Arginine Concentration Needed for Optimal Sensor
Translation
In order to determine concentrations of arginine needed for optimal sensor translation, WT and
LTATs of each cell line were treated with media containing varying concentrations of arginine,
and the fluorescence of GFP ArgSen was quantified by microscopy (Figure 2.5c). These
conditions limit the arginine concentrations of both WT and LTAT cells, as the media contains
no citrulline that could be used by ASS1 to synthesize arginine, and no cells outside of the small
intestine express all the necessary genes to synthesize citrulline de novo42. EC50s were found to
range from 2.59-8.10 µM (Figure 2.5d). To compare arginine sensor translation at various
arginine media concentrations to actual intracellular arginine concentrations with ADI-PEG20, a
combination of microscopy and flow cytometry was used to measure the diameters and calculate
the volumes of individual cells. Then intracellular concentrations of arginine were calculated
using metabolomics data and average cell volumes at 48 hours (Figures 2.5e and 2.5f). The
resulting figures were 13.9 µM of intracellular arginine for WT cells and 81.7 µM for LTAT
cells.

2.5 Discussion
The ArgSen is a new single-cell sensor to monitor real-time arginine-dependent protein
translation. Arginine starvation strategies are being developed clinically, but single agent use of
therapeutics like ADI-PEG20 has failed to translate to patients43. Therefore, an understanding of
the cellular adaption to arginine deprivation is an unmet need. By understanding the intracellular
dynamics of arginine starvation, a better understanding of when to add additional agents may
lead to better therapeutic strategies. Therefore, the development of the ArgSen will allow not
only for an understanding of the temporal dynamics of arginine starvation, but also the stromal
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response when multiple colored sensors are fully implemented in vitro and in vivo, which is the
subject of ongoing work.
The specificity of the ArgSen to arginine is supported by two experiments. First, the initial
response to arginine deprivation is greatly blunted when arginine residues in the polyarginine
motif are replaced by random non-arginine amino acids (RanSen). Second, glutamine
deprivation, while decreasing the maximal rate of translation, slows synthesis much more
gradually than arginine deprivation. These results indicate a preference and specificity of the
sensor for monitoring arginine-rich translation and support the idea that the dominant mechanism
of regulation is a decrease in translation. For use in other systems where arginine deficiency may
or may not be occurring, the RanSen may be used as a control for ArgSen to determine whether
the observed response is preferential for arginine availability.
The ArgSen demonstrates a rapid decrease in expression followed by a gradual recovery over
time in ASS1-deficient cells. The Fast-FT ArgSen and GFP ArgSen show some differences in
the magnitude of response to ADI-PEG20. This is likely attributable to the different mechanisms
by which their signals are degraded, as well as different methods of measurement, as average
GFP ArgSen fluorescence is susceptible to overestimation, as some cells fall below the detection
threshold.
In contrast to WT cells, resistant LTAT cells demonstrate no change in expression in response to
ADI-PEG20, as expected. This long-term resistance is conferred mostly by increased ASS1
expression. WT cells also show a short-term increase in ASS1 corresponding to ArgSen recovery
from ADI-PEG20 treatment. However, this increase in ASS1 expression likely does not totally
account for the increased sensor expression, as autophagy is known to help these cells cope with
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arginine starvation. Post-translational ASS1 activity regulation also cannot be ruled out. The
sensor is a more dynamic measure of resistance, as it increases significantly by 24 hours,
whereas ASS1 increases are small and difficult to measure at this early time point. Both continue
to increase thereafter.
The ArgSen model depends on constant sensor mRNA levels in the cell for reporter protein
levels to accurately reflect the ability of the cell to use arginine for translation. When measured
over a time course of ADI-PEG20 treatment, sensor mRNA levels do not significantly decrease
at any point, and the overall pattern of sensor fluorescence is very similar regardless of whether
it is normalized to mRNA, confirming that sensor protein expression levels are driven by
translation rather than transcription.
Next, while the full-length sensor possesses the shortest half-life and therefore the best temporal
resolution, deletion of some parts of the degradation domain still resulted in only marginally
longer half-lives, specifically when the polyarginine motif remained. We speculate that this is
because the polyarginine motif is likely disordered, and the presence of a disordered region is
critical and often sufficient for proteasomal degradation32,44,45.
Finally, CHX and BTZ worked as expected in sensor-expressing cells, rapidly depleting or
causing a buildup of the reporter protein, respectively. This supports the proposed mechanism of
the sensor that relies on both rapid synthesis and rapid degradation, leading to a relatively low
steady state level of reporter protein. Immunoblots further confirmed that the reporter protein is
indeed being degraded as designed.
Tracking of arginine sensor expression in individual ASS1-deficient cells demonstrated that
ADI-PEG20 treatment initially depleted the reporter protein in every cell analyzed, without
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exception. This is strong evidence that resistant cells are not present in naïve populations.
Subsequent recovery of expression indicates a metabolic adaptation in response to arginine
deprivation, but the magnitude of recovery varies widely. While population averages show a
slow recovery of expression back to roughly untreated levels by 72 hours, depending on the cell
line, single cell tracking reveals a diverse range of responses. After three days, many cells still
express very little arginine sensor, while some have roughly normal levels, and a few even
increased well past initial levels. The timing of recovery also varies among cells, with a small
subset gaining resistance earlier than most. These cells are present in all three cell lines, but they
are most prominent in SKUT1. Throughout the study, SKUT1 seemed to recover expression
more quickly than the other cell lines, which agrees with the fact that it has a higher basal level
of ASS1 expression28. These results overall show a fairly homogeneous initial response to ADIPEG20 followed by a heterogeneous recovery period wherein some cells increase expression
while others remain low.
When EC50s of arginine for sensor translation were measured, no difference between WT and
LTAT of the same cell line exceeded 2 µM, as LTAT cells are able to increase their supply of
arginine during ADI-PEG20 treatment rather than using it more efficiently. Measurements of
actual arginine concentrations in cells with ADI-PEG20 treatment suggest that LTATs are able
to maintain their concentrations of intracellular arginine at roughly five times the level of WT
cells. While SKLMS1 LTAT arginine levels are still far below those of untreated media (about
340 µM, shown in Supplemental Figure S2.4), the cells maintain a concentration that is nearly
twice their EC90, explaining why translation in LTATs is unaffected by ADI-PEG20. However,
the intracellular concentration of arginine in WT cells is substantially below this level when
treated with ADI-PEG20, which greatly inhibits protein translation.
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Interestingly, after the start of treatment with ADI-PEG20, citrulline takes many hours to reach a
steady intracellular concentration. This is likely because these cells do not readily transport
citrulline across the plasma membrane. WT cells maintain higher citrulline levels than LTATs,
likely as a result of faster conversion to arginine by ASS1 in LTATs. More importantly, and
unexpectedly, arginine levels did not significantly recover within 48 hours of ADI-PEG20
treatment. Pairing this with the previous data, arginine sensor expression is seen to increase in
WT cells while intracellular arginine concentrations remain constant. This seems contradictory,
but the most likely mechanism is that, after initial arginine depletion, synthesis of arginine
increases over time, and utilization of arginine increases to match, thereby maintaining a steady
concentration of arginine while increasing translation. We performed experiments to test this
hypothesis by inhibiting both translation and proteasomal degradation separately up to 48 hours
after the initiation of ADI-PEG20 treatment. The results showed that robust translation and
degradation continue throughout the course of arginine deprivation and that the sensor we have
designed measures adaptive resistance more accurately than actual intracellular arginine
concentrations by directly monitoring the ability of cells to use arginine for translation.

2.6 Conclusions
The ability to track responses in individual cells makes the sensor useful for the study of arginine
deprivation for clinical development. Using the sensor, multiple ASS1-deficient cell lines were
shown to completely lack resistance to ADI-PEG20 at the single cell level in naïve populations
but develop a heterogeneous pattern of resistance. This is promising for the potential
effectiveness of treatment with ADI-PEG20 and combination therapies with it. The finding that
resistance is heterogeneous suggests that temporally targeting the early response to ADI-PEG20
with additional drugs may yield a more effective, homogeneous response. Finally, the concept of
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the sensor could be applied to other amino acids through modification, having potential to be
used in the study of many other biological systems.
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Figure 2.1. Response to arginine deprivation in ASS1-deficient cells
a. Schematic overview of ADI-PEG20 treatment and response in ASS1-deficient cells. b. ASS1
expression with ADI-PEG20 treatment. c. Growth of cells with ADI-PEG20 treatment. d. Cell
death at 72 hours of ADI-PEG20 treatment. All error bars represent standard deviation.
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Figure 2.2. Design and demonstration of arginine sensor
a. Diagram of the main components of the arginine sensor. b. ArgSen fluorescence in SKLMS1
cells measured by flow cytometry. Error bars represent standard deviation. c. GFP ArgSen and
GFP RanSen fluorescence in SKLMS1 cells measured by microscopy. Error bars represent
standard deviation. d. Arginine sensor mRNA in SKLMS1 GFP ArgSen cells. Error bars
represent standard error of the mean. e. GFP ArgSen fluorescence with no treatment, glutamine
deprivation, ADI-PEG20 treatment, and ADI-PEG20 resistance in three cell lines. Error bars
represent standard deviation. f. GFP ArgSen fluorescence with ADI-PEG20 treatment for 12
hours, followed by normal media or continuation of treatment, in three cell lines. Error bars
represent standard deviation.
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Figure 2.3. Validating degradation of sensor
a. Degradation of GFP ArgSen and deletion variants in SKLMS1 in the presence of a translation
inhibitor (CHX). Error bars represent standard deviation. b. Best approximations of half-lives
with 95% confidence intervals calculated from data in a. ND = not determined. c. Representative
images of SKLMS1 GFP ArgSen fluorescence during treatment with ADI-PEG20, CHX, or a
proteasome inhibitor (BTZ). d. GFP ArgSen fluorescence in SKLMS1 cells with ADI-PEG20,
adding CHX at various time points. Error bars represent standard deviation. e. GFP ArgSen
fluorescence in SKLMS1 cells with ADI-PEG20, adding BTZ at various time points. Error bars
represent standard deviation. f. Immunoblots of GFP ArgSen protein in SKLMS1 over ADIPEG20 time course. g. Quantification of f, along with same data normalized to corresponding
mRNA levels from 2.2d. Error bars represent standard error of the mean.

54

55

Figure 2.4. Individual cell responses to arginine deprivation
a. GFP ArgSen fluorescence in individual cells over time in three cell lines. b. Representative
images of growth and GFP ArgSen fluorescence over three days with or without ADI-PEG20 in
three cell lines. c. Counts of cell fates and tiered changes in GFP ArgSen fluorescence at 4 and 24
hours with and without ADI-PEG20 in three cell lines.
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Figure 2.5. Effects of intracellular arginine concentrations on translation
a. Arginine concentrations in SKLMS1 WT and LTAT cells expressing GFP ArgSen over time
with ADI-PEG20 treatment as measured by mass spectrometry. b. Citrulline concentrations in
SKLMS1 WT and LTAT cells expressing GFP ArgSen over time with ADI-PEG20 treatment. c.
Average GFP ArgSen fluorescence over two hours with various concentrations of arginine in
media in three cell lines. Horizontal dotted lines indicate the values with ADI-PEG20 treatment.
Vertical dotted lines indicate calculated intracellular arginine concentrations after 48 hours of
ADI-PEG20 treatment. d. Effective concentration (EC) values for arginine driving translation of
GFP ArgSen in three cell lines, calculated from c. e. Histograms of cell volumes after 48 hours of
ADI-PEG20 treatment. f. Intracellular arginine concentrations after 48 hours of ADI-PEG20
treatment, along with values used to calculate concentrations. All error bars represent standard
deviation.
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Cell Line

Vendor

Catalog Number

SKLMS1

ATCC

HTB-88

SKUT1

ATCC

HTB-114

SKMEL2

ATCC

HTB-68

Supplemental Table S2.1
List of cell lines and sources.
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Antibody

Vendor

Catalog Number

ASS1

Polaris

gift

ASS1

Abcam

ab175607

GFP

Santa Cruz Biotechnology

sc-9996

Supplemental Table S2.2
List of antibodies and sources.
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Name

Sequence

EF1a fwd

TCAAGCCTCAGACAGTGGTTC

pKLV2 seq rev

CATAGCGTAAAAGGAGCAAC

pLV seq rev

CTTCGGCCAGTAACGTTAGG

Rad23b end fwd

GGTGACAAAGCCGAAAGC

SalI BamHI FastFT fwd

GACGTGGAGGAGAACCCTGGACCTGTCGACGGATCCAT
GAGTAAGGGCGAGGAGGATAAC

NotI NLS FastFT rev

ATCCAGAGGTTGAGCGGCCGCTTATACCTTACGCTTCTTC
TTTGGCTTGTAAAGCTCATC

SalI BamHI GFP fwd

GACGTGGAGGAGAACCCTGGACCTGTCGACGGATCCAT
GGTGAGCAAGGGCGAGGAGCTG

NotI NLS GFP rev

ATCCAGAGGTTGAGCGGCCGCTTATACCTTACGCTTCTTC
TTTGGCTTGTACAGCTCGTC

Proteasomal del fwd

CGCGCCCACCATGGCGTT

Proteasomal del rev

CGAACGCCATGGTGGG

Disordered del fwd

CGCGCCCACCATGGCGGGTATGCA

Disordered del rev

TACCCGCCATGGTGGG

Rad23b del fwd

TGCTAGCGGATTCGAAT

Rad23b del rev

CTAGATTCGAATCCGCTAGCATGCA

Reporter only fwd

CGCGCCCACCATGGCGG

Reporter only rev

GATCCCGCCATGGTGGG

qrtPCR GAPDH fwd

CGGATTTGGTCGTATTGGGC

qrtPCR GAPDH rev

CCGTTCTCAGCCATGTAGTTG

qrtPCR ArgSen fwd

CGAACGTCTTCAAGGGGACA

qrtPCR ArgSen rev

GTATCGGGCACAAAGCCAAC
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Supplemental Table S2.3
List and full sequences of DNA oligonucleotides used in this study.
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Supplemental Figure S2.1
Global protein translation rates in SKLMS1 WT over 12 hours with no treatment, ADI-PEG20,
glutamine deprivation, or ADI-PEG20 plus glutamine deprivation. Error bars represent standard
deviation.
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Supplemental Figure S2.2
GFP ArgSen fluorescence and growth over 72 hours with ADI-PEG20 treatment in ASS1F/F and
ASS1-/- MEFs. Error bars represent standard deviation.
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Supplemental Figure S2.3
Analysis of GFP ArgSen fluorescence in subsets of dividing cells from Figure 2.4. Five untreated
cells and roughly 20 ADI-PEG20-treated cells from each cell type were tracked, along with all
their descendants, for 24 and 72 hours respectively, excluding cells that could not be tracked
with confidence. Data points represent the average green fluorescence of cells at the indicated
timepoint, calculated from the averages of each initial cell or its trackable descendants at that
time. Error bars represent standard error of the mean.
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[Arginine] (µM)

400

No Treatment
ADI-PEG20

300
200
100
0
WT

LTAT

Supplemental Figure S2.4
Concentrations of arginine in MEM after 72 hours with SKLMS1 WT and LTAT cells with and
without ADI-PEG20 treatment. Bars for ADI-PEG20-treated media are not visible because
values are too low. Error bars represent standard deviation.

67

2.7 References
1

Haines, R. J., Pendleton, L. C. & Eichler, D. C. Argininosuccinate synthase: at the center
of arginine metabolism. Int J Biochem Mol Biol 2, 8-23 (2011).

2

Wu, G. & Morris, S. M. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336 (
Pt 1), 1-17 (1998).

3

Dillon, B. J. et al. Incidence and distribution of argininosuccinate synthetase deficiency
in human cancers. Cancer 100, 826-833, doi:10.1002/cncr.20057 (2004).

4

Qiu, F. et al. Arginine starvation impairs mitochondrial respiratory function in ASS1deficient breast cancer cells. Science signaling 7, ra31, doi:10.1126/scisignal.2004761
(2014).

5

Qiu, F., Huang, J. & Sui, M. Targeting arginine metabolism pathway to treat argininedependent cancers. Cancer Lett 364, 1-7, doi:10.1016/j.canlet.2015.04.020 (2015).

6

Patel, V. B., Preedy, V. R. & Rajendram, R. L-Arginine in Clinical Nutrition. (Humana
Press, 2016).

7

Rabinovich, S. et al. Diversion of aspartate in ASS1-deficient tumors fosters de novo
pyrimidine synthesis. Nature 527, 379-383, doi:10.1038/nature15529 (2015).

8

Holtsberg, F. W., Ensor, C. M., Steiner, M. R., Bomalaski, J. S. & Clark, M. A.
Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations
on its pharmacological properties. Journal of Controlled Release 80, 259-271,
doi:10.1016/S0168-3659(02)00042-1 (2002).

9

Oginsky, E. L. & Gehrig, R. F. The arginine dihydrolase system of Streptococcus
faecalis. II. Properties of arginine desimidase. The Journal of biological chemistry 198,
799-805 (1952).

10

Tsai, W.-B. et al. Resistance to arginine deiminase treatment in melanoma cells is
associated with induced argininosuccinate synthetase expression involving c-Myc/HIF1alpha/Sp4. Molecular Cancer Therapeutics 8, 3223-3233, doi:10.1158/15357163.MCT-09-0794 (2009).

11

Tsai, W.-B. et al. Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to
Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in
Melanoma Cells. Cancer Research 72, 2622-2633, doi:10.1158/0008-5472.CAN-113605 (2012).

68

12

Bean, G. R. et al. A metabolic synthetic lethal strategy with arginine deprivation and
chloroquine leads to cell death in ASS1-deficient sarcomas. Cell Death & Disease 7,
e2406, doi:10.1038/cddis.2016.232 (2016).

13

Delage, B. et al. Promoter methylation of argininosuccinate synthetase-1 sensitises
lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
Cell Death & Disease 3, e342, doi:10.1038/cddis.2012.83 (2012).

14

Huang, H.-Y. et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas:
aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative
prognostic impact, and therapeutic relevance. Clin. Cancer Res. 19, 2861-2872,
doi:10.1158/1078-0432.CCR-12-2641 (2013).

15

Long, Y. et al. Cisplatin-induced synthetic lethality to arginine-starvation therapy by
transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc
transcription network and is independent of ASS1 promoter DNA methylation.
Oncotarget 7, 82658-82670, doi:10.18632/oncotarget.12308 (2016).

16

Prudner, B. C. et al. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1
Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Clin Cancer Res, doi:10.1158/1078-0432.ccr-19-0206 (2019).

17

Verma, N., Singh, A. K. & Singh, M. L-arginine biosensors: A comprehensive review.
Biochem Biophys Rep 12, 228-239, doi:10.1016/j.bbrep.2017.10.006 (2017).

18

Hartenbach, S., Daoud-El Baba, M., Weber, W. & Fussenegger, M. An engineered larginine sensor of Chlamydia pneumoniae enables arginine-adjustable transcription
control in mammalian cells and mice. Nucleic Acids Research 35, e136,
doi:10.1093/nar/gkm652 (2007).

19

Wang, S. et al. The amino acid transporter SLC38A9 is a key component of a lysosomal
membrane complex that signals arginine sufficiency to mTORC1. Science 347, 188-194,
doi:10.1126/science.1257132 (2015).

20

Saxton, R. A., Chantranupong, L., Knockenhauer, K. E., Schwartz, T. U. & Sabatini, D.
M. Mechanism of arginine sensing by CASTOR1 upstream of mTORC1. Nature 536,
229-233, doi:10.1038/nature19079 (2016).

21

Li, X. & Yan, X. Sensors for the mTORC1 pathway regulated by amino acids*. J
Zhejiang Univ Sci B 20, 699-712, doi:10.1631/jzus.B1900181 (2019).

22

Jewell, J. L. & Guan, K. L. Nutrient Signaling to mTOR and Cell Growth. Trends
Biochem Sci 38, 233-242, doi:10.1016/j.tibs.2013.01.004 (2013).

23

Lee, F. & Yanofsky, C. Transcription termination at the trp operon attenuators of
Escherichia coli and Salmonella typhimurium: RNA secondary structure and regulation
69

of termination. Proceedings of the National Academy of Sciences of the United States of
America 74, 4365-4369 (1977).
24

Darnell, A. M., Subramaniam, A. R. & O’Shea, E. K. Translational control through
differential ribosome pausing during amino acid limitation in mammalian cells. Mol Cell
71, 229-243 e211, doi:10.1016/j.molcel.2018.06.041 (2018).

25

Technical Library :: ProteinSimple,
<https://www.proteinsimple.com/technical_library.html?product=004600&doctype=user_guides&def_list=list> (2020).

26

Tzelepis, K. et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and
Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep 17, 1193-1205,
doi:10.1016/j.celrep.2016.09.079 (2016).

27

Hayer, A. et al. Engulfed cadherin fingers are polarized junctional structures between
collectively migrating endothelial cells. Nat Cell Biol 18, 1311-1323,
doi:10.1038/ncb3438 (2016).

28

Kremer, J. C. et al. Arginine Deprivation Inhibits the Warburg Effect and Upregulates
Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. Cell Reports
18, 991-1004, doi:10.1016/j.celrep.2016.12.077 (2017).

29

Kaufman, W. L. et al. Homogeneity and persistence of transgene expression by omitting
antibiotic selection in cell line isolation. Nucleic Acids Research 36, e111,
doi:10.1093/nar/gkn508 (2008).

30

Subach, F. V. et al. Monomeric fluorescent timers that change color from blue to red
report on cellular trafficking. Nat. Chem. Biol. 5, 118-126, doi:10.1038/nchembio.138
(2009).

31

Wilmington, S. R. & Matouschek, A. An Inducible System for Rapid Degradation of
Specific Cellular Proteins Using Proteasome Adaptors. PLOS ONE 11, e0152679,
doi:10.1371/journal.pone.0152679 (2016).

32

Peña, Maria Marjorette O., Xing, Yang Y., Koli, S. & Berger, Franklin G. Role of Nterminal residues in the ubiquitin-independent degradation of human thymidylate
synthase. Biochemical Journal 394, 355-363, doi:10.1042/BJ20051479 (2006).

33

Fishbain, S. et al. Sequence composition of disordered regions fine-tunes protein halflife. Nature structural & molecular biology 22, 214-221, doi:10.1038/nsmb.2958 (2015).

34

van der Lee, R. et al. Intrinsically Disordered Segments Affect Protein Half-Life in the
Cell and during Evolution. Cell Reports 8, 1832-1844, doi:10.1016/j.celrep.2014.07.055
(2014).
70

35

Mizianty, M. J. et al. Improved sequence-based prediction of disordered regions with
multilayer fusion of multiple information sources. Bioinformatics 26, i489-496,
doi:10.1093/bioinformatics/btq373 (2010).

36

Mizianty, M. J. et al. In-silico prediction of disorder content using hybrid sequence
representation. BMC Bioinformatics 12, 245, doi:10.1186/1471-2105-12-245 (2011).

37

Mizianty, M. J., Peng, Z. & Kurgan, L. MFDp2: Accurate predictor of disorder in
proteins by fusion of disorder probabilities, content and profiles. Intrinsically Disord
Proteins 1, e24428, doi:10.4161/idp.24428 (2013).

38

Karlin, D., Ferron, F., Canard, B. & Longhi, S. Structural disorder and modular
organization in Paramyxovirinae N and P. Journal of General Virology 84, 3239-3252,
doi:10.1099/vir.0.19451-0 (2003).

39

Communie, G. et al. Structure of the Tetramerization Domain of Measles Virus
Phosphoprotein. J. Virol. 87, 7166-7169, doi:10.1128/JVI.00487-13 (2013).

40

Gerard, F. C. A. et al. Modular Organization of Rabies Virus Phosphoprotein. Journal of
Molecular Biology 388, 978-996, doi:10.1016/j.jmb.2009.03.061 (2009).

41

Kim, J. H. et al. High Cleavage Efficiency of a 2A Peptide Derived from Porcine
Teschovirus-1 in Human Cell Lines, Zebrafish and Mice. PLOS ONE 6, e18556,
doi:10.1371/journal.pone.0018556 (2011).

42

Wakabayashi, Y. Tissue-selective expression of enzymes of arginine synthesis. Curr
Opin Clin Nutr Metab Care 1, 335-339, doi:10.1097/00075197-199807000-00004
(1998).

43

Abou-Alfa, G. K. et al. Phase III randomized study of second line ADI-PEG 20 plus best
supportive care versus placebo plus best supportive care in patients with advanced
hepatocellular carcinoma. Ann Oncol 29, 1402-1408, doi:10.1093/annonc/mdy101
(2018).

44

Prakash, S., Tian, L., Ratliff, K. S., Lehotzky, R. E. & Matouschek, A. An unstructured
initiation site is required for efficient proteasome-mediated degradation. Nature
Structural and Molecular Biology 11, 830, doi:10.1038/nsmb814 (2004).

45

Yu, H., Kago, G., Yellman, C. M. & Matouschek, A. Ubiquitin‐like domains can target to
the proteasome but proteolysis requires a disordered region. The EMBO Journal 35,
1522-1536, doi:10.15252/embj.201593147 (2016).

71

Chapter 3: Macropinocytosis from the
Microenvironment Enables Growth of
Arginine Auxotrophic Tumors in the
Absence of Extracellular Arginine
This chapter is based on a manuscript of the same name that is in preparation for publication at
the time of writing.
Contributing authors are Leonard Rogers, Jeff Kremer, Zhixian Hu, Adriana Baker, Nicole
Fettig, Kooresh Shoghi, John Chrisinger, Carina Dehner, Eileen White, and Brian Van Tine.

3.1 Abstract
A common metabolic abnormality in cancer is arginine auxotrophy caused by silencing of the
rate limiting enzyme argininosuccinate synthetase 1 (ASS1) in the urea cycle. Here, conditional
Ass1 knockout (KO) in a spontaneous murine sarcoma model affected neither tumor initiation
nor growth rates, contradicting the prevalent idea that ASS1 silencing confers a proliferative
advantage in vivo. Use of extracellular arginine deprivation therapy has encouraged studies of the
metabolic adaptations that cause resistance. Classically, resistance occurs by upregulating ASS1,
allowing tumors to synthesize arginine directly. Here, Ass1 KO cells grew robustly through
arginine starvation in vivo, but died in vitro. Co-culture with Ass1-competent fibroblasts rescued
growth through macropinocytosis of vesicles and/or cell fragments, followed by recycling of
protein-bound arginine. This process was inhibited in vivo by imipramine or chloroquine. This
identifies a new ASS1-independent resistance mechanism to arginine deprivation and
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demonstrates complete microenvironmental compensation for amino acid deprivation therapy in
vivo.

3.2 Introduction
The enzyme argininosuccinate synthetase 1 (ASS1) is essential for both humans and mice to
synthesize arginine, an amino acid that is required for protein synthesis and survival. However,
most solid tumors, including many hepatocellular carcinomas, prostate cancers, bladder cancers,
small cell lung cancers, and melanomas, amongst others, lack a functional level of ASS1, making
it one of the most commonly silenced genes in cancers1–6. This is also true of sarcomas, with
over 85% being deficient in this enzyme7. Lack of ASS1 causes these tumors to be auxotrophic
for arginine, relying on the naturally plentiful extracellular supply for growth and survival.
Studies have shown that ASS1 downregulation can confer proliferation advantages, particularly
by reducing aspartate consumption by ASS1 and diverting it towards pyrimidine synthesis8.
However, this has not been established as the reason for frequent silencing of ASS1 in tumors,
nor has it been shown to affect initiation or growth in a spontaneous tumor model. In the case of
sarcomas, where this phenotype is frequent, the cells of origin should be considered. For
example, ASS1 is essentially undetectable in muscle, from which many sarcomas originate, and
is also low in adipose tissue9. This study directly investigates the effects of a conditional
knockout of Ass1 in a spontaneous murine sarcoma model.
Despite the advantage that ASS1 deficiency might confer to tumors in a typical environment, this
characteristic makes tumors metabolically vulnerable to arginine deprivation. PEGylated
arginine deiminase (ADI-PEG20) is an enzymatic drug that degrades extracellular arginine to
citrulline. Treatment with ADI-PEG20 has little effect on most normal cells because they express
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a functional level of ASS1 to convert citrulline back into arginine as part of the urea cycle.
However, ASS1-deficient cancer cells, with their high demand for arginine and inability to
synthesize it, enter a starvation state and become cytostatic4,6,7,10–12. They must adapt to survive
or die.
Upregulation of autophagy in response to ADI-PEG20 has been shown to compensate in tumor
cells without an extracellular source of arginine4,6,7,13,14. This adaptation is driven by low levels
of intracellular arginine inhibiting mTORC1 that in turn causes autophagy to increase.
Autophagy can recycle arginine within the cell and provide enough nutrients to sustain the cell in
the short term.
In order to gain long term resistance to arginine deprivation therapy, studies have shown that
these cancers simply increase their expression of ASS1, often through a c-Myc-dependent
mechanism, which is possible because the gene is typically epigenetically repressed rather than
being mutated or deleted3,7,11,15. In fact, ASS1 upregulation is the only published mechanism of
long-term resistance in this system.
The ultimate required metabolic adaptation in this system is that cancer cells acquire an adequate
supply of arginine to grow and proliferate. This may not necessarily be achieved solely by
upregulating ASS1 and synthesizing more arginine. There are a multitude of other mechanisms
by which cancer cells could theoretically acquire arginine16. Among others, macropinocytosis,
necrocytosis, receptor-mediated endocytosis, phagocytosis, entosis, extracellular vesicle transfer,
nutrient sharing through gap junctions, and arginine secretion by nearby cells provide plentiful
possibilities16–28. It is unclear which, if any, of these mechanisms have the capacity to supply a
sufficient amount of arginine for tumors to progress in the absence of plasma arginine. Which
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mechanism is best able to provide cancer cells with nutrients under starvation conditions has not
been fully elucidated, but a recent report suggests that macropinocytosis helps to overcome
similar aspartate limitations29. Most import mechanisms would also require the newly acquired
materials to be broken down by autophagy/lysosomal degradation to produce free arginine to
incorporate into new proteins.
This study defines the first alternative mechanism for resistance to arginine starvation whereby
the microenvironment supports tumor growth in the absence of ASS1 expression.

3.3 Results
3.3.1 Arginine starvation fails to inhibit protein translation in vivo
As has been demonstrated previously in ASS1 deficient sarcoma cell lines7,10, the proliferation of
human sarcoma cell line SKLMS1 is significantly perturbed when treated with ADI-PEG20
(Figure 3.1a) because of very low to no ASS1 expression (Figure 3.1c). Although it slows
growth, ADI-PEG20 does not cause meaningful death in these cells (Figure 3.1b). SKLMS1 can
become resistant to ADI-PEG20 with long-term exposure by upregulating the expression of
ASS1, and resistant cells are called LTAT (long-term ADI-PEG20-treated) (Figure 3.1c).
To test the kinetics of resistance, we tested intracellular arginine-dependent translational capacity
of SKLMS1 under arginine starvation conditions. mApple, chosen for its ability to serve as a
reporter protein for both in vitro and in vivo experiments, was cloned into a previously published
lentiviral construct for reporting the availability of arginine for translation within cells12.
Matching previously published data using other reporters12, ADI-PEG20 caused a rapid decrease
in expression of the sensor mApple reporter in vitro compared to no treatment (Figure 3.1d). In
contrast, despite the fact that ADI-PEG20 slowed growth similarly in vitro and in vivo (Figures
75

3.1a and 3.1e), no decrease in sensor expression was found in vivo (Figure 3.1f). Representative
sensor fluorescence images are shown in Supplemental Figure S3.1a.
Metabolite measurements revealed that ADI-PEG20 was indeed very effective in vivo,
decreasing arginine levels in serum to near zero within two days and suppressing them for the
duration of treatment (Figure 3.1g). Correspondingly, citrulline levels increased and reached a
steady state within 7 days (Figure 3.1h). Metabolite measurements in the tumors showed a
similar but less dramatic pattern, with the tumors losing 81% of their arginine by two days and
90% by 15 days (Figure 3.1i). Citrulline levels likewise increased in the tumors as in the serum
(Figure 3.1j).
These decreased arginine concentrations resulting from ADI-PEG20 treatment caused metabolic
changes in the tumors. To confirm that a metabolic shift to glutamine biology was still occurring
in vivo as shown previously in vitro10, positron emission tomography (PET) was used to estimate
utilization of glutamine by the tumors by measuring the uptake of analog molecule 18F-(2S,4R)4fluoroglutamine (18F-(2S,4R)4-FGln). ADI-PEG20 indeed caused increased uptake of glutamine
in SKLMS1 tumors (Supplemental Figures S3.2b and S3.2c). This suggests that the metabolic
shifts caused by ADI-PEG20 hold in this system, but that cells in the intratumoral environment
rapidly compensate for the loss of arginine and are able to maintain arginine-dependent
translation.

3.3.2 ASS1 deficiency is not advantageous for spontaneous murine sarcomas
In order to better understand the effects of the loss of ASS1 on tumor biology, a genetic model
was made with Myf5-driven Cre expression causing recombination of floxed p53 genes in both
groups and floxed Ass1 genes in only one group of a spontaneous murine sarcoma experiment,
resulting in nonfunctional protein products (Figure 3.2a). Most resulting tumors were identified
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morphologically as rhabdomyosarcomas, and a significant proportion were osteosarcomas
(Supplemental Table S3.1a), with images shown in Figures 3.2b and 3.2c. Knocking out Ass1 did
not significantly change the rate of tumor initiation in this sarcoma model (Figure 3.2d).
Likewise, the difference in growth rates between the two groups was not significant (Figure
3.2e).
When ASS1 protein was measured by immunoblot of frozen tumors, all Ass1 null tumors had
low ASS1 (Figure 3.2f). A small amount of ASS1 was detected in these tumors, indicating the
presence of stromal cells that did not express Myf5-Cre and therefore had an intact Ass1 gene. 18
of 26 (69%) Ass1 WT tumors also expressed ASS1 at a level lower than the highest-expressing
Ass1 null tumor (Figure 3.2f). This group of tumors was then segregated along this dividing line
for further analysis. There was a trend toward sooner initiation in tumors with high ASS1, and
when compared to Ass1 null tumors, the ASS1 high tumors appeared significantly sooner (Figure
3.2g). ASS1 high tumors also had significantly higher growth rates than ASS1 low tumors
(Figure 3.2h).

3.3.3 Cells without ASS1 grow robustly through arginine deprivation in vivo
but die in vitro
Cell lines were made from many of the spontaneous sarcomas from Figure 3.2 (Supplemental
Table S3.1b). Those cell lines with low ASS1 from both Ass1 null and WT tumors were shown
to be highly sensitive to ADI-PEG20 and unable to proliferate after several hours, while many
cells died within the first few days of treatment (Figures 3.3a and 3.3b). Not all Ass1 WT tumor
cell lines died with ADI-PEG20 treatment, as BVM03O showed only slowed proliferation
(Figure 3.3a), similar to SKLMS1, likely due to its higher level of ASS1 (Supplemental Figure
S3.2a). ASS1 low cell lines differed in their responses to long-term ADI-PEG20 treatment
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depending on their genotype. Ass1 null cell lines invariably died completely when treated with
ADI-PEG20, while all Ass1 WT cell lines developed resistance over weeks to months of
treatment.
To determine the effects of ADI-PEG20 on the proliferation of Ass1 null cells in vivo, multiple
Ass1 null murine sarcoma cell lines were injected subcutaneously into either syngeneic
C57BL/6J mice or NU/J mice. There, very little effect of ADI-PEG20 was found in NU/J mice in
two of the three cell lines tested, whereas ADI-PEG20 seemed to slow but not stop growth in
immune-competent syngeneic C57BL/6J mice (Figures 3.3c and 3.3d and Supplemental Figure
S3.2b). Crucially, Ass1 null tumors from all tested cell lines were able to grow robustly through
ADI-PEG20 treatment in vivo while the drug remained 100% lethal to their parental cell lines in
vitro, illustrating a stark contrast in the effectiveness of ADI-PEG20 between the different
environments and explaining the in vivo arginine sensor data (Figure 3.1f).

3.3.4 Ass1 KO tumor cell growth is enabled by macropinocytosis of EVs from
ASS1-competent MEFs during arginine deprivation
To further investigate this phenomenon, BVMA01R Ass1 null tumors that had grown through
ADI-PEG20 were taken ex vivo and made into cell lines. These cells remained sensitive to ADIPEG20 in vitro (Figure 3.4a) and could not survive long-term treatment. When cultured on a
feeder layer of mouse embryonic fibroblasts (MEFs), these cells were more resistant to death,
and the shown cell line from mouse 1037 (1037 tumor cells) accepted support from the MEFs
well enough to proliferate through ADI-PEG20 treatment (Figure 3.4a). All tested ASS1 low cell
lines showed a similar ability to accept growth support from fibroblasts during ADI-PEG20
treatment, including Ass1 WT murine sarcoma lines (Supplemental Figures S3.3a and S3.3b).
The human sarcoma cell lines SKLMS1 and SKUT1, which expresses slightly more ASS110,
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also accepted support from human fibroblasts (Supplemental Figures S3.3c and S3.3d). While
the observed growth support was far less robust than what tumors received in vivo, this model
provided an opportunity to investigate the mechanisms by which arginine auxotrophic cell
proliferation could be supported by other cells in the absence of free extracellular arginine.
Co-culturing 1037 tumor cells with MEFs rather than growing them on a MEF feeder layer
provided a similar growth support effect (Figure 3.4b). This effect could not be sustained unless
the MEFs expressed ASS1 (Figure 3.4b). Knockout of Ass1 in MEFs was validated in
Supplemental Figures S3.4a-S3.4d. Multiple possible mechanisms of growth support were
investigated, and it was found that neither MEF-conditioned media nor inhibition of gap
junctions or clathrin-mediated endocytosis could recreate or prevent the growth support
phenomenon, respectively (Supplemental Figures S3.5a-S3.5c). When MEFs were stained with a
green fluorescent membrane dye, large fragments of MEF membranes were seen disconnected
from their cells of origin, making contact with the tumor cells, showing that cell fragments and
extracellular vesicles (EVs) could likely be transferred from MEFs to tumor cells (Figure 3.4c).
To test whether this was a major mechanism by which MEFs supported tumor cell growth, EVs
were isolated from MEFs and added to 1037 tumor cells in the presence of ADI-PEG20. These
EVs protected from death and supported growth similarly to co-cultured MEFs (Figure 3.4d).
Further, the EV production inhibitor EST completely abrogated the growth supportive effect of
MEFs (Figure 3.4e) while not affecting the growth of the MEFs themselves in the presence of
ADI-PEG20 (Supplemental Figure S3.5d), indicating that the growth support was not diminished
because of decreased MEF viability. Another EV production inhibitor, imipramine, had a similar
effect to EST (Figure 3.4f), even though the two inhibitors target different pathways of EV
production30,31.
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This may be due to the fact that imipramine can also inhibit macropinocytosis32. Therefore, we
tested the effect of imipramine on the uptake of fluorescently labeled membranes from MEFs
into 1037 cells. Indeed, we found that imipramine significantly decreased the amount of
membrane that 1037 cells took from the media over 24 hours when treated with ADI-PEG20
(Figure 3.4g). Because of its apparent inhibition of macropinocytosis in this model, directly
targeting the tumor cells, along with its proven track record of safe use in both mice and humans,
imipramine was tested for its ability to slow growth of BVMA01R tumors in vivo in combination
with ADI-PEG20. The combination of ADI-PEG20 and imipramine significantly slowed tumor
growth, while either single agent did not (Figure 3.4h). This was not due to lower ASS1
expression, as no treatment group differed significantly in tumor ASS1 levels compared to
untreated (Figure 3.4i).

3.3.5 Autophagy/lysosomal degradation is required for cells receiving but not
cells supplying growth support
As ingested proteins must be degraded by tumor cells to obtain useful arginine, the
autophagy/lysosomal degradation inhibitor chloroquine was tested with the co-culture of 1037
cells and MEFs to determine whether autophagy was essential to the growth support process.
Chloroquine completely inhibited growth of the tumor cells in co-culture with MEFs and ADIPEG20 (Figure 3.5a).
In order to determine whether autophagy was essential for the growth support process in the
tumor cells, MEFs, or both, two MEF cell lines were generated with either Atg7 or Fip200
floxed. These genes were then knocked out with Cre to inhibit autophagy specifically in the
MEFs (Figures 3.5b and 3.5c and Supplemental Figures S3.4e-S3.4g). The effects on co-culture
growth support were tested, and both floxed cell lines were able to support proliferation of 1037
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cells in the presence of ADI-PEG20. Atg7 KO MEFs supported growth to a lesser extent than
their floxed counterparts, while Fip200 KO MEFs were completely unable to support growth
(Figures 3.5d and 3.5e). These results mirrored the effects of the gene knockouts on the MEFs
themselves, as the Atg7 KO MEFs stayed relatively healthy in the presence of ADI-PEG20,
while the Fip200 KO MEFs died rapidly due in part to extremely low ASS1 (Supplemental
Figures S3.4e and S3.4h). To separate the effects of MEF viability from the effects of MEF
autophagy, GFP-ASS1 was exogenously expressed in these same cell lines, giving them ample
resistance to ADI-PEG20 (Supplemental Figures S3.4e and S3.4i). The ASS1-expressing floxed
MEFs provided slightly more growth support than their Ass1 WT counterparts (Figures 3.5d and
3.5e), and ASS1 expression rescued the ability of Atg7 and Fip200 KO MEFs to provide growth
support (Figures 3.5d and 3.5e).
When BVMA01R tumors were treated in vivo with both ADI-PEG20 and chloroquine, only the
combination significantly slowed tumor growth (Figure 3.6f). Again, this was shown to not be
due to a difference in tumor ASS1 levels among the groups, as none significantly differed from
untreated (Figure 3.6g). RNA sequencing of these tumors revealed many differentially regulated
genes (Supplemental Figure S3.6a) and pathways. Relevant pathways are shown in Supplemental
Figure S3.6b. Notably, ADI-PEG20 greatly increased expression of genes related to cell
adhesion, supporting the observation that ADI-PEG20 promoted cell-cell contacts and clustering
of these cells in vitro, an effect that was more prominent in the presence of MEFs (Supplemental
Figure S3.6c). Phagosome and lysosome pathways were also upregulated, supporting the
hypothesis that the tumor cells uptake and digest bulk nutrients from outside the cell. Strikingly,
18 of the 20 most differentially regulated pathways with ADI-PEG20 treatment are upregulated,
with the cell cycle pathway being a notable exception (Supplemental Figure S3.6d).
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Additionally, 13 of the 20 pathways are related to the immune system, which may indicate
increased immune cell infiltration, a possibility that is under current investigation.

3.4 Discussion
Based on the published literature describing the lack of ASS1 in many cancers and the potential
advantages this condition confers, knocking out Ass1 in addition to p53 in a murine sarcoma
model was expected to result in faster initiation and/or faster growth of tumors. This was not the
case, largely because of the naturally low levels of ASS1 in most of the Ass1 WT tumors. In
retrospect, the fact that the spontaneous murine sarcoma model roughly recapitulated the finding
of naturally low ASS1 in most human sarcomas should have been expected. Muscle, the main
tissue of tumor origin in this model, expresses as little ASS1 any tissue in the body9. This fact
combined with the results of this study suggest that the main reason for a lack of ASS1 in many
sarcomas is simply inheritance of suppressed ASS1 expression from their cells of origin. This
interpretation conflicts with studies showing advantages of ASS1 suppression in cancer cells8,33.
In fact, ASS1 upregulation gives an advantage to tumors in this model, which opposes prevailing
thought on the topic, and is the focus of further investigation.
When using arginine deprivation therapy to target ASS1-deficient cancers, it was surprising that
SKLMS1 tumors did not decrease their translational capacity when treated with ADI-PEG20 in
vivo. This was the first bit of evidence indicating that the in vitro and in vivo environments may
prove to be crucially different in the context of arginine deprivation therapy. When all tested
Ass1 KO tumors were able to grow rapidly through ADI-PEG20 treatment in multiple mouse
strains, it was clear that a novel mechanism of resistance to arginine deprivation therapy must be
responsible. The evidence pointed strongly toward microenvironmental metabolic support of
tumor growth.
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This metabolic adaptation to ADI-PEG20 was then confirmed to not be intrinsic to the cancer
cells, but could be recapitulated to a lesser extent in vitro by co-culturing tumor cells with ASS1competent MEFs, further supporting the hypothesis of microenvironmental growth support.
While most major routes of possible nutrient transfer were tested, experiments showed that the
most important path in this system in vitro is likely the excretion of EVs and/or cell fragments
from MEFs and subsequent uptake of these membrane-bound particles into tumor cells by
macropinocytosis, followed by recycling of the proteins within to supply the tumor cells with
arginine (Figure 3.6). This recycling seems to be achieved largely through autophagy/lysosomal
degradation, as shown by the results of chloroquine treatment. It was further determined that the
mechanism of growth support does not require autophagy in the cells providing the support but
rather the cells receiving the nutrients.
These findings result in new clinical opportunities for ADI-PEG20 combination therapies and
clinical trials. Autophagy proved critical enough in this system that chloroquine had pronounced
synergy in slowing tumor growth in combination with ADI-PEG20 in vivo. Imipramine, an
inhibitor that theoretically targets the tumors more specifically than chloroquine in this system,
largely by inhibiting macropinocytosis, also showed clear synergy with ADI-PEG20 in vivo.
Additionally, RNA sequencing strongly suggests that ADI-PEG20 recruits immune cells to
tumors, which makes combination with immune therapy a very promising avenue for future
research.
This study also elucidates the magnitude of the ability of the microenvironment to metabolically
support tumor growth. The system featured totally arginine-auxotrophic cancer cells, in
conditions that would otherwise be lethal, growing through ADI-PEG20-induced arginine
starvation robustly with the help of host cells that were able to synthesize arginine and provide it
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to the tumor. Some experiments even showed no apparent effect of ADI-PEG20 on the growth of
the Ass1 KO tumors, indicating the magnitude to which this phenomenon can assist tumors. To
our knowledge, there have been no reports of microenvironmental tumor growth support to this
extent.
Overall, we have identified a new noncanonical mechanism for ADI-PEG20 resistance and a first
step in metabolic adaptation to ADI-PEG20. While re-expression of ASS1 via c-Myc expression
is the canonical adaptation mechanism, macropinocytosis alleviates tumors acutely as the first
step in overcoming arginine starvation in arginine-auxotrophic tumors. These findings explain
the negative phase 3 clinical trials in some cancers such as hepatocellular carcinoma (HCC),
where ADI-PEG20 was found to lower circulating arginine levels but not to affect tumor
progression-free survival or overall survival. Additionally, this work suggests that new clinical
trials using chloroquine, imipramine, or a combination of both with ADI-PEG20 in HCC may
overcome the ability of the microenvironment to compensate for ADI-PEG20-induced
starvation.
As has become clear from multiple clinical trials, amino acid starvation in arginine-auxotrophic
tumors requires multiple agents. Currently, ADI-PEG20 is being tested in combination with
pemetrexed and cisplatin in mesothelioma (NCT02709512)34 and with docetaxel and
gemcitabine in sarcoma (NCT pending)35. The observations in this study suggest that the
addition of chloroquine or imipramine to these regiments would prevent macropinocytosis and
increase the efficacy of arginine starvation as a therapeutic. The complexity of cancer metabolic
redundancies is demonstrating that development of agents such as ADI-PEG20 will require not
only a full understanding of metabolic adaptations, but also that we must target the urea cycle
and the adaptive pathways simultaneously.
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3.5 Methods
3.5.1 Spontaneous Murine Sarcoma Model
Ass1F/F mice were bred as previously described12. Strain #008462 p53F/F mice were obtained
from The Jackson Laboratory (Bar Harbor, ME)36. Strain #010529 Myf5-Cre mice were also
obtained from The Jackson Laboratory37. Mice were bred so that all experimental mice were
females that were heterozygous for Myf5-Cre and homozygous p53F/F. The indicated mice were
bred to also be homozygous Ass1F/F.
Experimental mice were carefully checked for tumors two times per week. All discovered tumors
were measured with calipers at least every other day, and volume was calculated as half of length
X width2. Growth of each tumor was fitted in GraphPad Prism (GraphPad Software, San Diego,
CA) to the following exponential growth equation:
𝑌 = 𝑌0 ∗ 𝑒 𝑘∗𝑋

(3.1)

where 𝑌0 is the Y value when X (time) is 0, and 𝑘 is the rate constant of growth. Graphs of tumor
growth with a fitted curve used this same method and constrained 𝑌0 to the mean of the Y values
on Day 0.
All small animal experiments were approved by the Animal Studies Committee at Washington
University School of Medicine, and all protocol guidelines were followed. Tumors in this study
were harvested only when a protocol endpoint was reached while the mouse was alive. A portion
of each harvested tumor was fixed in 10% neutral buffered formalin and embedded in paraffin. 5
µm thick slides were cut for hematoxylin and eosin (H&E) staining where shown. All tumor
histology classifications were done blindly by a trained pathologist. Another portion of each
harvested tumor was flash frozen in liquid nitrogen and stored at -80° C.
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3.5.2 Cell Line Generation
Ass1F/F MEFs were generated as previously described12. Cell lines were generated from tumors
as follows. Tissue was taken from the interior of the tumor, minced, washed, and incubated in
0.25% Trypsin-EDTA (Thermo Fisher Scientific, Waltham, MA) at 4° C overnight. Trypsin was
then aspirated, and tissue pieces were incubated with residual trypsin at 37° C for 30 min. Tissue
pieces were then dispersed by pipetting with warm, complete I-20 media (described below),
filtered through sterile 100 µm nylon mesh, and plated in I-20 media. Cells were then grown and
passaged before being used for experiments.

3.5.3 Cell Culture
SKLMS1, SKUT1, and HDFa cell lines were obtained from the American Type Culture
Collection (Manassas, VA). Atg7F/F MEFs were generated from Atg7F/F mice, which were made
and provided by Dr. M. Komatsu (Tokyo Metropolitan Institute of Medical Science)38,39.
Fip200F/F MEFs were generated from Atg200F/F mice40,41. All MEFs used in experiments were
first spontaneously immortalized as previously described12. All LTAT cells were developed by
passaging cells normally with 1 µg/mL ADI-PEG20 (Polaris Pharmaceuticals, San Diego, CA)
until growth rate stabilized. SKLMS1 and SKUT1 cells were grown in media consisting of MEM
(Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) (Bio-Techne, Minneapolis, MN),
1% 100X penicillin/streptomycin (Thermo Fisher Scientific), and 2.5 µg/mL Plasmocin
(InvivoGen, San Diego, CA). All other cell lines were grown in I-20 media, consisting of IMDM
(Thermo Fisher Scientific) with 20% FBS, 1% 100X penicillin/streptomycin, 1% 100X MEM
nonessential amino acids (Corning, Corning, NY), 0.0007% 2-mercaptoethanol (MilliporeSigma,
St. Louis, MO), and 2.5 µg/mL Plasmocin. Phenol red-free versions of these media were used for
any experiment requiring quantification of green fluorescence. Cells were grown in a cell culture
incubator with 5% CO2 at 37° C.
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Cell line experiments were conducted in 96-well plates and started the day after plating except
where indicated. For these plates, cells were plated at a density per well of 3,000 for SKLMS1,
HDFa, and MEFs; 5,000 for murine tumor cell lines; and 7,500 for SKUT1. For co-culture
experiments, cells were plated and allowed to settle and attach together. The growth media of the
cell line being counted was used when cell lines in the same well typically used different media.
Feeder layers of cells were plated two days before the start of the experiment and treated with
mitomycin C (MMC) (MilliporeSigma) the next day, immediately before the tumor cells were
seeded on top.
MMC treatment was performed by adding 10 µg/mL MMC to cells for 2 hours at 37° C, then
washing three times with DPBS (Thermo Fisher Scientific). DiOC18(3) (3,3'Dioctadecyloxacarbocyanine Perchlorate) (Thermo Fisher Scientific) staining was performed
according to the manufacturer’s instructions. All in vitro ADI-PEG20 treatment was done with
media that had been pre-treated with 1 µg/mL ADI-PEG20 overnight at 37° C. EST (aloxistatin)
(MedChemExpress, Monmouth Junction, NJ), imipramine (MilliporeSigma), chloroquine
(MilliporeSigma), tonabersat (Cayman Chemical Company, Ann Arbor, MI), carbenoxolone
(Apexbio Technology, Houston, TX), and Pitstop 2 (MilliporeSigma) were administered at the
indicated concentrations, and controls were treated with the same volume of vehicle.

3.5.4 Vesicle Uptake Assay
3X106 DiOC18(3)-stained or unstained MEFs were plated in a 10-cm dish, and 10 mL phenol
red-free media was added the next day and left on for 24 hours. Media was then taken off MEFs
and centrifuged for 5 min at 200 X g, and the supernatant was collected. Conditioned media for
the supplemental growth support experiment was obtained in the same way with unstained
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MEFs, plating them at the same density per cm2 and adding the same depth of media as in the
96-well plates, and treating with MMC before conditioning media.
MMC-treated BVMA01R cells were plated in a 96-well plate at 15,000 cells per well, and media
collected from MEFs was pre-treated with ADI-PEG20 and added to the BVMA01R cells with
or without imipramine. This media was collected again after 24 hours, and DiOC18(3)
fluorescence was measured on a Tecan Infinite M200 plate reader (Tecan, Männedorf,
Switzerland). Data was normalized so that 0% represented the average fluorescence of
conditioned media from unstained MEFs and 100% represented the average fluorescence of
media from stained MEFs, both without being added to BVMA01R cells.

3.5.5 Extracellular Vesicle Isolation
MEFs were plated on five 10-cm dishes of 8X105 cells each. The next day, 5 mL of media was
added to each plate for 24 hours, then harvested with Total Exosome Isolation Reagent (from cell
culture media) (Thermo Fisher Scientific) according to the manufacturer’s instructions. Isolated
EVs were resuspended in ADI-PEG20 pre-treated media and added to 1037 cells in a 96-well
plate at the indicated concentrations.

3.5.6 Automated Cell Imaging
All automated cell imaging was done on cells in 96-well plates with either an Incucyte ZOOM
(Sartorius, Göttingen, Germany) or Incucyte S3 (Sartorius) automated cell imaging system. Cells
that were counted were first transduced with either Incucyte® Nuclight Red Lentivirus (EF1a,
Puro) (Sartorius) or Incucyte® Nuclight Green Lentivirus (EF1a, Puro) (Sartorius) and selected
with puromycin for stable expression. Incucyte software was used to count the red or green
nuclei of transduced cells to measure the number of live cells at each timepoint. The cell
impermeable DNA-binding dye YOYO™-1 Iodide (Thermo Fisher Scientific) was used to stain
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dead cells and was quantified in the same way. mApple ArgSen expression was measured as the
average integrated intensity of the nuclei.

3.5.7 Immunoblotting
Cells were plated at 1X105 cells per well of a 6-well plate for all immunoblot experiments. Fresh
media was added the next day, and the cells were harvested 24 hours later. Cell pellets were
lysed in 1X Cell Lysis Buffer (Cell Signaling Technology, Danvers, MA) with 1X Halt™
Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific) added. Mouse tissues
were lysed in 2X Cell Lysis Buffer with 1X Halt™ Protease and Phosphatase Inhibitor Cocktail.
Tissues were mashed with Biomasher II® Disposable Micro Tissue Homogenizers (DWK Life
Sciences, Millville, NJ). After resuspension or homogenization in lysis buffer, samples were
incubated on ice for 20 min with periodic vortexing, then sonicated. Samples were centrifuged at
21,130 X g at 4° C for 10 min, and the supernatant was collected. Samples were run on a Wes
automated immunoblot machine (Bio-Techne) according to the manufacturer’s instructions,
using the primary antibodies indicated in Supplemental Table S3.2a. Protein amounts were
quantified with Compass software for Simple Western (Bio-Techne) and normalized to total
protein.

3.5.8 Cloning
All primer sequences are listed in Supplemental Table S3.2b. Primers were ordered from
Integrated DNA Technologies (Coralville, IA). The mApple gene was PCR amplified from
plasmid mApple-N1 (Addgene, Watertown, MA) with SalI BamHI mApple fwd and NotI NLS
mApple rev primers to add restriction sites and a C-terminal nuclear localization signal. mAppleN1 was a gift from Michael Davidson (Addgene plasmid #54567; http://n2t.net/addgene:54567;
RRID: Addgene_54567)42. The amplicon was then cloned into the pKLV2-EF1a-GFP ArgSen
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plasmid (Addgene plasmid #184695)12 with restriction sites BamHI and NotI, replacing EGFP
with mApple. The sensor gene with mApple reporter was then subcloned into the pLV-EF1aGFP ArgSen plasmid (Addgene plasmid #184704)12, completely replacing the original insert.
This pLV-EF1a-mApple ArgSen plasmid was used for experiments.
The EGFP gene was PCR amplified with BamHI EGFP fwd and BglII EGFP rev primers, then
cloned into the MSCV puro plasmid (Plasmid #68469)43 by digesting BglII on the vector and C
terminus of the insert, and BamHI (compatible with BglII) on the N terminus of the insert,
followed by ligation. Cloning destroyed the N terminal restriction site and preserved the C
terminal BglII site. MSCV Puro was a gift from Tyler Jacks (Addgene plasmid #68469;
http://n2t.net/addgene:68469; RRID: Addgene_68469). ASS1 cDNA was then PCR amplified
from a HEK 293T cDNA library with ASS1 fwd and ASS1 rev primers. This PCR product was
further amplified while adding restriction sites with BglII ASS1 fwd and MfeI ASS1 rev primers.
This was then cloned into the MSCV EGFP puro plasmid with BglII on the N terminus of the
insert, linking the ASS1 and EGFP genes, and leaving the C terminus of the insert undigested and
ligating with the blunt end left by HpaI digestion of the vector. The resulting GFP-ASS1 fusion
sequence was then PCR amplified with AscI EGFP fwd and NotI ASS1 rev primers and cloned
into the pLV vector with AscI and NotI restriction sites.
All cloned constructs were integrated into lentiviruses and used to transduce the indicated cells,
which were selected with puromycin.

3.5.9 In Vivo Arginine Sensor
1.5 million SKLMS1 cells expressing mApple ArgSen were grafted subcutaneously into female
NU/J mice (Strain #002019, The Jackson Laboratory) 4-6 weeks of age. All subcutaneous grafts
in this study were done by suspending cells in media, mixing 1:1 with Matrigel (Corning), and
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injecting 100 µL under the skin on the flank. mApple ArgSen mice were fed an alfalfa-free, low
fluorescence diet, the Teklad global 18% protein diet (Inotiv, West Lafayette, IN). Treatment and
imaging were started after tumors reached 200 mm3. Images of mApple fluorescence were
acquired by a Bruker Multispectral FX Pro system (Bruker, Billerica, MA), and images were
analyzed with Fiji software (fiji.sc).

3.5.10 Tumor Growth Experiments
5 million of the indicated cells were grafted subcutaneously into female C57BL/6J (Strain
#000664, The Jackson Laboratory) or NU/J mice 4-6 weeks of age. Treatments began after
tumors reached 200 mm3. ADI-PEG20 treatments were administered by intramuscular injection
as 13 µL of 11 mg/mL ADI-PEG20 every three days. Imipramine was dissolved in 138 mM
NaCl at 30 mg/mL and administered intraperitoneally (IP) at 30 mg/kg/day. Chloroquine was
dissolved in DPBS at 20 mg/mL and administered IP at 60 mg/kg/day. Mice were euthanized
after 30 days of treatment or when tumors reached 1,600 mm3 for the imipramine experiment or
2,000 mm3 for the chloroquine experiment.

3.5.11 Gene Knockout
Ass1-/- MEFs and Ass1F/F controls were generated as previously described12. Atg7F/F and
Fip200F/F MEFs were infected with either Ad5CMVCre or Ad5CMVempty adenoviral particles
(University of Iowa, Iowa City, IA) to recombine and knock out the floxed genes or serve as
negative controls, respectively. Cells were lysed for genotyping with DirectPCR Lysis Reagent
(Cell) (Viagen Biotech, Los Angeles, CA) following the manufacturer’s instructions. Ass1
genotyping used Ass1 del fwd, Ass1 FF fwd, and Ass1 geno rev primers. Atg7 genotyping used
Atg7 geno fwd, Atg7 FF rev, and Atg7 del rev primers. Fip200 genotyping used Fip200 del fwd,
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Fip200 FF fwd, and Fip200 geno rev primers. All gene knockouts were also validated by
immunoblot.

3.5.12 Metabolomics
Blood and tumors were harvested from NU/J mice harboring SKLMS1 tumors at the indicated
timepoints. Blood was allowed to clot at room temperature for 30 min, then centrifuged at 1,500
X g for 10 min at 4° C. The supernatant serum was collected and immediately stored at -80° C.
Tumors were flash frozen upon harvesting and stored at -80° C. Samples were shipped on dry ice
for metabolomic analysis at Human Metabolome Technologies America (Boston, MA).

3.5.13 RNA Sequencing
RNA was isolated from frozen tumor samples with the Direct-zol RNA Miniprep Plus kit (Zymo
Research, Irvine, CA). RNA samples were submitted to the Genome Technology Access Center
at the McDonnell Genome Institute (GTAC@MGI) of Washington University in St. Louis.
GTAC@MGI prepared the RNA using the KAPA RiboErase method, sequenced with an
Illumina NovaSeq sequencer (Illumina, San Diego, CA), and analyzed with their standard RNAseq analytical pipeline.

3.5.14 Positron Emission Tomography
Female NU/J mice harboring SKLMS1 tumors (n=4) underwent small animal positron emission
tomography (PET) imaging one day prior to ADI-PEG20 administration (NT) and 13 days after
starting treatment. The mice were anesthetized with 1% isoflurane/oxygen followed by dynamic
PET acquisition at 0-60 min after intravenous tail injection of 8-12 MBq of 18F-(2 S,4 R)4-FGln
using the INVEON imaging system. The animals were deprived of food for four hours prior to
the 18F-(2 S,4 R)4-FGln studies. The animals were maintained at 37° C during the study using a
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warming lamp. Computed tomography (CT) images were also acquired with the INVEON
system.
The PET data were analyzed by manually drawing 3-dimensional regions of interest (ROIs) over
the tumor identified on the PET studies with correlation to CT to confirm the tumor location. The
uptake data were expressed as mean standardized uptake values (SUVs) for each ROI at 50-60
min after injection of 18F-(2 S,4 R)4-FGln.

3.5.15 Quantification and Statistical Analysis
Statistical tests were performed in GraphPad Prism 9 software. Differences between time series
were analyzed by 2-way ANOVA, using a mixed model when necessary. Grouped data were
analyzed by Mann-Whitney test, Kolmogorov-Smirnov test, paired t test, or unpaired t test as
appropriate. Time-to-event data were analyzed by Log-rank (Mantel-Cox) test. All error bars
show standard deviation, except tumor growth error bars show standard error of the mean. All
statistical details of experiments can be found in the figure legends. P-values are denoted in the
following way: ns: p > 0.05; *: p ≤ 0.05; **: p ≤ 0.01; ***: p ≤ 0.001; ****: p ≤ 0.0001.
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Figure 3.1. Arginine starvation fails to inhibit protein translation in vivo
a. Proliferation of SKLMS1 cells with and without ADI-PEG20 treatment in vitro. b. Death of
SKLMS1 cells with and without ADI-PEG20 treatment in vitro. c. ASS1 expression in WT and
LTAT SKLMS1 cells. d. Expression of mApple ArgSen in SKLMS1 cells with and without ADIPEG20 treatment in vitro. e. Growth of SKLMS1 tumors with and without ADI-PEG20 treatment
in NU/J mice. f. Expression of mApple ArgSen in SKLMS1 tumors with and without ADIPEG20 treatment in NU/J mice. See also Supplemental Figure S3.1a. g. Serum arginine
concentrations of NU/J mice treated with ADI-PEG20. h. Serum citrulline concentrations of
NU/J mice treated with ADI-PEG20. i. SKLMS1 tumor arginine concentrations from NU/J mice
treated with ADI-PEG20. j. SKLMS1 tumor citrulline concentrations from NU/J mice treated
with ADI-PEG20. Data are mean ± s.d. except in e (mean ± s.e.m.) (n = 12 in a, b; n = 3 in c, g-j;
n = 8-12 in d; n = 12-24 in e; n = 6 in f). Two-way ANOVA tests except in c (two-tailed unpaired
t-test).
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Figure 3.2. ASS1 deficiency is not advantageous for spontaneous murine sarcomas
a. Ass1 knockout genetic schema and example genotyping result. Gel image is cropped for
clarity. b. Example H&E stainings of spontaneous murine rhabdomyosarcomas from both control
and Ass1 KO groups. Numbers indicate mouse IDs. Scale bar = 100 µm. c. Example H&E
stainings of spontaneous murine osteosarcomas from both control and Ass1 KO groups. Numbers
indicate mouse IDs. Scale bar = 100 µm. d. Tumor-free survival plot of both control and Ass1
KO groups. e. Growth rates of tumors from both control and Ass1 KO groups. f. ASS1
expression of tumors from both control and Ass1 KO groups. g. Tumor-free survival plot of Ass1
KO group along with control mice segregated (along dotted line in f) by ASS1 expression in their
tumors. h. Growth rates of tumors of control group mice segregated by ASS1 expression in the
tumors. Data are mean ± s.d. (replicates as shown). Log-rank tests for d, g. Mann-Whitney tests
for e, f, h.
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Figure 3.3. Cells without ASS1 grow robustly through arginine deprivation in vivo but die
in vitro
-/-

+/+

a. Proliferation in vitro with and without ADI-PEG20 of three Myf5-Cre;p53 ;Ass1 cell lines
isolated from spontaneous murine sarcomas. b. Proliferation in vitro with and without ADI-/-/PEG20 of three Myf5-Cre;p53 ;Ass1 cell lines isolated from spontaneous murine sarcomas. c.
Tumor growth of Ass1 KO BVMA01R grafts in both C57BL/6J and NU/J mice with and without
ADI-PEG20 treatment. d. Tumor growth of Ass1 KO BVMA02R grafts in both C57BL/6J and
NU/J mice with and without ADI-PEG20 treatment. Data are mean ± s.d. in a (n = 4), b (n = 12),
mean ± s.e.m. in c, d (n = 3-4). Two-way ANOVA tests. See also Supplemental Figure S3.2.
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Figure 3.4. Ass1 KO tumor cell growth is enabled by macropinocytosis of EVs from ASS1competent MEFs during arginine deprivation
a. Proliferation of Ass1 KO murine sarcoma cell line (1037) taken ex vivo after growing through
ADI-PEG20 treatment in vivo. 1037 cells die when treated with ADI-PEG20, but they grow
through ADI-PEG20 when cultured on feeder layers of various numbers of MMC-treated MEFs.
b. Proliferation of 1037 cells when treated with ADI-PEG20 and co-cultured with MEFs that
have Ass1 either floxed or knocked out. See also Supplemental Figures S3.4a-S3.4d. c. Images of
1037 cells with red nuclei co-cultured with MEFs with green-stained membranes. Yellow arrows
indicate examples of large fragments of MEFs contacting 1037 cells. Images are cropped for
clarity. d. Proliferation of 1037 cells when treated with ADI-PEG20 with or without the addition
of EVs isolated from MEFs. e. Fold change in number of live 1037 cells after 96 hours of
treatment with ADI-PEG20 with and without both co-cultured MEFs and 25 µM EST. See also
Supplemental Figure S3.5d. f. Fold change in number of live 1037 cells after 96 hours of
treatment with ADI-PEG20 with and without both co-cultured MEFs and 25 µM imipramine. g.
Uptake of MEF EVs by 1037 cells with or without 20 µM imipramine during ADI-PEG20
treatment. More fluorescence remaining in media indicates less uptake. h. Growth of BVMA01R
tumors grafted into syngeneic C57BL/6J mice with and without both ADI-PEG20 and
imipramine treatments. i. Quantification of ASS1 levels in harvested tumors from h. Data are
mean ± s.d. except in h (mean ± s.e.m.) (n = 2 in a; n = 3 in b, e, f, g; n = 4 in d; n = 5-12 in h; n
= 3-6 in i). Two-way ANOVA tests for a, b, d, h. Two-tailed paired t-tests for e, f, g. Two-tailed
unpaired t-test for i.
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Figure 3.5. Autophagy/lysosomal degradation is required for cells receiving but not cells
supplying growth support
a. Proliferation of 1037 cells when treated with ADI-PEG20 with and without both co-cultured
F/F
MEFs and 20 µM chloroquine. b. Genotyping of Atg7 MEFs infected with adCre to trigger
F/F
recombination of the floxed gene or adEmpty as a control. c. Genotyping of Fip200 MEFs
infected with adCre to trigger recombination of the floxed gene or adEmpty as a control. d. Fold
change in number of live 1037 cells after 72 hours of treatment with ADI-PEG20 with and
without co-cultured MEFs having Atg7 either floxed or knocked out, along with each of these
MEF cell lines overexpressing GFP-ASS1. e. Fold change in number of live 1037 cells after 72
hours of treatment with ADI-PEG20 with and without co-cultured MEFs having Fip200 either
floxed or knocked out, along with each of these MEF cell lines overexpressing GFP-ASS1. d and
e were performed simultaneously and used the same controls. f. Growth of BVMA01R tumors
grafted into syngeneic C57BL/6J mice with and without both ADI-PEG20 and chloroquine
treatments. g. Quantification of ASS1 levels in harvested tumors from f. Data are mean ± s.d.
except in f (mean ± s.e.m.) (n = 3 in a; n = 4-8 in d, e; n = 9-10 in f; n = 8-10 in g). Two-way
ANOVA tests for a, f. Two-tailed unpaired t-tests for d, e, g. Images are cropped for clarity. See
also Supplemental Figures S3.4e-S3.4i.
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Figure 3.6. Overview of growth support
Tumor stromal cells produce extracellular vesicles that contain proteins and other nutrients.
During arginine deprivation therapy, ASS1-deficient cancer cells take up these EVs and use
autophagy/lysosomal degradation to recycle the ingested proteins and produce sufficient free
arginine for survival and growth. Created with BioRender.com.
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Supplemental Figure S3.1. In vivo imaging
a. Representative fluorescence images of SKLMS1 tumors expressing mApple ArgSen in NU/J
mice with and without ADI-PEG20 treatment. b. Quantified uptake of 18F-(2 S,4 R)4-FGln
radioactive glutamine tracer measured by PET before and after 13 days of ADI-PEG20 treatment
in SKLMS1 tumors grafted into NU/J mice. c. Computed tomography/PET combination images
of mice from b with tumors outlined in red. Data are mean ± s.d. (n = 4). Two-tailed paired t-test.
Images are cropped for clarity.
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Supplemental Table S3.1. Tumor histology classifications and derived cell lines
a. All harvested spontaneous murine sarcomas were stained with hematoxylin and eosin, then
classified according to morphology by a trained pathologist. Counts and percentages are shown.
b. Cell lines generated from spontaneous murine sarcomas. Cell line name, mouse of origin,
genotype, morphological classification, and other notes are listed.
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Supplemental Figure S3.2. ASS1 expression in spontaneous murine sarcoma cell lines and
growth of Ass1 KO tumors in vivo
a. Quantification of ASS1 immunoblots for six spontaneous murine sarcoma cell lines featured
in Figures 3.3a and 3.3b. b. Tumor growth of Ass1 KO BVMA03R grafts in NU/J mice with and
without ADI-PEG20 treatment. Data are n = 1 in a, mean ± s.e.m. in b (n = 3-4).

106

Supplemental Figure S3.3. Fibroblasts support growth of Ass1 WT murine and human
sarcoma cell lines
a. Proliferation of Myf5-Cre;p53-/-;Ass1+/+ BVM01R cell line when treated with ADI-PEG20
with or without a feeder layer of MEFs. b. Proliferation of Myf5-Cre;p53-/-;Ass1+/+ BVM02R
cell line when treated with ADI-PEG20 with or without a feeder layer of MEFs. c. Proliferation
of human sarcoma cell line SKLMS1 when treated with ADI-PEG20 with or without a feeder
layer of adult human dermal fibroblasts (HDFa). d. Proliferation of human sarcoma cell line
SKUT1 when treated with ADI-PEG20 with or without a feeder layer of HDFa cells. Data are
mean ± s.d. (n = 4). Two-way ANOVA tests.
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Supplemental Figure S3.4. Validation of gene knockouts and ASS1 expression in MEFs
a. Genotyping of Ass1F/F MEFs infected with adCre to trigger recombination of the floxed gene
or adLacZ as a control. b. ASS1 immunoblots of Ass1F/F, Ass1-/-, and Ass1F/F LTAT MEFs. c.
Quantification of b. d. Proliferation of Ass1F/F and Ass1-/- MEFs when treated with ADI-PEG20.
e. Immunoblots of ATG7, FIP200, exogenous GFP-ASS1, and endogenous ASS1 in MEFs
expressing GFP-ASS1 with either Atg7 or Fip200 floxed or knocked out. f. Quantification of
ATG7 in MEFs with Atg7 floxed or knocked out. g. Quantification of FIP200 in MEFs with
Fip200 floxed or knocked out. h. Quantification of endogenous ASS1 in all four MEF lines from
e. i. Quantification of GFP-ASS1 in all four MEF lines from e. Data are mean ± s.d. (n = 3 in c, fg; n = 15 in d). Two-tailed Welch’s t-test for c. Two-way ANOVA test for d. Two-tailed ratio
paired t-tests for f, g. Images are cropped for clarity.
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Supplemental Figure S3.5. Evidence against other possible growth support mechanisms
and MEF toxicity
a. Proliferation of 1037 cells when treated with ADI-PEG20 in either normal media or media
conditioned by MEFs. b. Proliferation of 1037 cells when treated with ADI-PEG20 with and
without co-cultured MEFs and the gap junction inhibitors carbenoxolone (50 µM) and tonabersat
(50 µM). c. Proliferation of 1037 cells when treated with ADI-PEG20 with and without cocultured MEFs and the clathrin-mediated endocytosis inhibitor Pitstop 2 (80 µM). d.
Proliferation of MEFs co-cultured with 1037 cells with ADI-PEG20 treatment and with or
without 25 µM EST. Data are mean ± s.d. (n = 3 in a, d; n = 4 in b, c). Two-way ANOVA tests.
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Supplemental Figure S3.6. RNA sequencing of tumors
a. BVMA01R tumors from C57BL/6J mice were harvested, and their RNA was sequenced.
Shown is a volcano plot of gene expression when tumors were treated with ADI-PEG20 versus
no treatment. b. Changes in expression of RNAs belonging to three pathways when tumors were
treated with ADI-PEG20, chloroquine, or both. c. Images showing the effects of ADI-PEG20 on
1037 cells over 24 hours alone or in co-culture with MEFs. d. Top 20 most differentially
regulated pathways from RNA sequencing data with ADI-PEG20 treatment. Red coloring
indicates pathways that are related to the immune system. (n = 3 in a, b, d.)
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Supplemental Table S3.2. Antibodies and primers
a. Antibodies used for immunoblots. Antibody target, vendor, and catalog number are listed. b.
Primers used for polymerase chain reactions. Primer names and 5’→3’ sequences are listed.
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Chapter 4: Future Directions
The work detailed in this dissertation has elucidated the mechanisms, heterogeneity, and kinetics
of both canonical and noncanonical mechanisms of resistance to arginine deprivation therapy in
cancer. Just as it has answered many questions, it has spurred an even larger number of new
ones. Many of these new questions are quite interesting and deserve to be explored further. To
that end, some promising future directions for research building on the work presented in this
dissertation are outlined here.

4.1 Arginine Sensor
The arginine sensor described in Chapter 2 effectively tracked the availability of arginine for
translation within cells. However, the design leaves room for improvement in multiple ways.
Firstly, improvements to the degradation domain are likely possible to allow more rapid
degradation of the reporter and thereby grant greater temporal resolution to the sensor. An
improved degradation domain may also be simpler and/or smaller, which should improve the
performance of the sensor. At least one design has been shown to degrade GFP with a half-life of
less than 15 minutes1. Therefore, it may be possible to implement a similar design to increase the
efficiency of degradation of the arginine sensor.
In order to control for changes in global translation rates, two reporter proteins may be
incorporated into the sensor, with only one reporter downstream of the polyarginine region. This
could take the form of one reporter downstream and one upstream of the polyarginine region, so
that the upstream reporter is affected by global translation rates, and the downstream reporter is
affected in roughly the same way by global translation, with the additional effect of slowed
translation when arginine specifically is scarce. These two reporters would likely be most
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effective if separated by a P2A site, each with their own degradation domain, but could still
function if connected.
Alternatively, the arginine sensor could be expressed under the control of a specific internal
ribosome entry site (IRES) that changes expression very little in response to global signals such
as mTOR inhibition. Cricket paralysis virus IRES requires no initiation factors to initiate
translation of its mRNA and would therefore be nearly ideal for this purpose2. This design would
insulate sensor expression from changes in global protein expression. Combining the previous
two ideas of using an IRES and a second fluorescent protein as a control may yield even better
performance than using either alone.
It is also tempting to expand on the concept of the arginine sensor design to create sensors for the
availability of other amino acids in cells. This would theoretically be easy to achieve by
swapping out the polyarginine region for a region encoding a different amino acid or even a
combination of amino acids. Asparagine and glutamine may be targets of interest for these
efforts, but other amino acids could be used as well.
However, there may be a limited number of amino acids for which this sensor design is useful
under physiologically relevant conditions. For example, some amino acids may become limiting
for other cellular processes and cause cell death at higher concentrations than would cause a
decrease in translation rate. Situations such as this would require a more complicated system to
isolate the effects of amino acid concentration on translation and are unlikely to yield results that
give useful physiological insight.
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4.2 Microenvironmental Growth Support
The arginine sensor led to the discovery of a new mechanism of resistance to arginine
deprivation. Chapter 3 describes the basic mechanisms underlying this phenomenon, namely that
Ass1 KO cancer cells overcome arginine starvation by endocytosing extracellular vesicles
through macropinocytosis, then degrading the proteins contained within those vesicles through
autophagy/lysosomal degradation and recycling the resulting arginine. However, much
elucidation remains to be done, including the determination of which particular host cells provide
most of the growth support in vivo.
To answer this question, conditional knockout of Ass1 could be performed in specific subsets of
murine host cells that typically make up a significant portion of tumors, such as fibroblasts,
monocytes, and endothelial cells. The effects of ADI-PEG20 on growth of Ass1 KO tumors in
these mice could then be tested. Alternatively, subsets of cells could be depleted completely,
such as using a mouse line that lacks monocytes. After identifying the most important cell
type(s) for in vivo growth support, co-culture experiments could be performed with that cell type
in vitro to validate the findings.
Further, the role of macropinocytosis in the growth support mechanism should be elucidated
more rigorously. Macropinocytosis can be measured by adding fluorescently labeled high
molecular weight dextran, a marker of macropinocytosis, to cells in culture and imaging
macropinosomes. First, the effects of imipramine on macropinocytosis in Ass1 KO cancer cells
should be measured directly with this method to further confirm that imipramine is acting mainly
through macropinocytosis inhibition.
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There are no known proteins that function only in macropinocytosis, which would be ideal
targets to knock out in order to inhibit macropinocytosis specifically3. Therefore, a double point
mutant of KR987/989AA in CARMIL1, an actin capping protein regulator, could be made with
CRISPR. This double mutation inhibits macropinocytosis while leaving most other functions of
CARMIL1 unaffected3. The effects of these mutations on co-culture growth support and
macropinocytosis could then be tested.
The importance of macropinocytosis in vivo must also be confirmed more specifically. To do
this, the effects of ADI-PEG20 on the growth of CARMIL1 mutant tumors could be tested. In
addition, it would be useful to inject fluorescent dextran into these tumors and harvest them to
visualize macropinocytosis in vivo. This should be done with both WT and CARMIL1 mutant
tumors and after treatment with ADI-PEG20 and/or imipramine.
Additionally, the importance of EVs must be shown in vivo. After identifying important cell
types for tumor growth support in vivo, one could proceed to determine the dominant pathway of
EV production for that cell type in vitro. This could be done by separately treating the cells with
inhibitors that target all three major pathways of EV production, then measuring the effects on
EV production by isolating vesicles and measuring abundance with nanoparticle tracking
analysis. If an effective inhibitor is found, it could be used in vivo in combination with ADIPEG20 while the effects on Ass1 KO tumor growth are measured. For a more targeted approach,
one could generate a mouse line with a critical gene in the important EV production pathway
knocked out in the relevant cell type, then test tumor growth support with ADI-PEG20 in those
mice.
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It would also be beneficial to identify the specific components of EVs that are critical for growth
support. The most likely factor is the bulk protein content contained within the vesicles, a rich
source of arginine. Synthetic liposomes can help test the importance of these proteins as well as
other factors, as they can be loaded with different components of EVs individually, then added to
cancer cells to test their ability to rescue growth. To test whether the protein or lipid content of
the EVs can support growth, liposomes could be loaded with high concentrations of protein such
as bovine serum albumin or fatty acids or other lipids. To further separate the effects of proteins
from the membranes of the liposomes, the cell culture media could simply contain a large
concentration of soluble protein. This may be more difficult with lipids if they are poorly
soluble. Liposomes could also be used to test the effects of other molecules, such as purified
ASS1 enzyme.
Albeit bulk protein is likely the main factor, Ass1 mRNA and enzyme are also plausible
contributors to growth support that may be transferred from ASS1-competent cells to Ass1 KO
cells through EVs. To test this hypothesis, one could isolate vesicles from MEFs with intact or
knocked out Ass1 genes and test their ability to support Ass1 KO cancer cell growth with ADIPEG20. If no difference is found, then likely neither Ass1 mRNA nor enzyme is a contributing
factor in vivo. Optionally, EVs could be isolated from Ass1 KO MEFs expressing large amounts
of exogenous WT or mutant ASS1. If EVs from MEFs with WT ASS1 support growth better,
then mRNA and/or enzyme would be shown to theoretically be able to help in large enough
amounts. One could then attempt to distinguish between the effects of mRNA and enzyme by
expressing Ass1 shRNA in the recipient cancer cells.
Finally, it would be useful to knock out ASS1 in multiple human cell lines and determine whether
the same growth support phenomenon occurs in a wide variety of cancers. This would give
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insight into how clinically impactful this mechanism is, as most cancers have intact ASS1 genes
and are able to upregulate it to achieve long-term resistance to ADI-PEG20. If most cancer lines
are shown to be able to overcome arginine deprivation therapy by scavenging arginine from
extracellular vesicles in vivo, it will increase the urgency to find therapies that effectively
synergize with ADI-PEG20 to kill.

4.3 Impact of Arginine Starvation on the Immune
Microenvironment
To that end, the effects of ADI-PEG20 on the immune system and potential for synergy with
immunotherapies also deserve to be explored. After RNA sequencing of tumors indicated a large
increase in immune-related gene signatures during ADI-PEG20 treatment, analysis using
advanced computational models developed in the laboratory of Dr. Everett Moding confirmed
that ADI-PEG20 caused an increase in immune cell infiltration of tumors. This preliminary data
shows increases in multiple immune cell types, including both pro-tumor and antitumor subsets.
This suggests that immune checkpoint inhibitors may be effective in combination with ADIPEG20.
To further elucidate the changes caused by ADI-PEG20 in the immune component of tumors,
immunohistochemistry (IHC) could be performed to identify changes in immune markers and
immune evasion markers, especially PD-1 and PD-L1. In addition, the tumor cell lines isolated
from the spontaneous murine sarcoma model detailed in Chapter 3 of this dissertation could be
screened for immune evasion markers. The effect of ADI-PEG20 on growth of selected cell lines
with various levels of immune evasion markers (likely PD-L1) could then be measured in vivo in
both immune-competent syngeneic mice and immune-deficient mice. Sensitivity to ADI-PEG20
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in immune-competent mice but not immune-deficient mice would indicate that ADI-PEG20 may
be slowing growth by stimulating the immune antitumor response. This seems to be the case with
at least one cell line from Chapter 3. Cell lines with low expression of immune evasion markers
would be expected to be more sensitive to immune attack in this model.
Selected tumor cell lines that are susceptible to ADI-PEG20-induced immune attack in vivo
could then be co-cultured with multiple types of immune cells in vitro while measuring the
effects of ADI-PEG20 on immune cell responses to the tumor cells. This would help elucidate
which immune cells are mediating the antitumor response in vivo. Cells could then be grown in
syngeneic mice with different immune components knocked out (e.g. B cells, T cells,
monocytes). If the effect of ADI-PEG20 is diminished, that would indicate that the knocked out
immune component in that particular mouse model is important for mediating the antitumor
response.
While cells that are sensitive to ADI-PEG20-induced immune attack can help elucidate the
mechanisms of the immune response, cells that are less responsive, likely with higher expression
of immune evasion markers, are likely to be more responsive to combination therapies of ADIPEG20 with immune checkpoint inhibitors. The sensitivity of these cells to combination therapy
should therefore be tested both in co-culture with relevant immune cells and in immunecompetent mice. A suitable combination therapy may be ADI-PEG20 with an anti-PD-1
antibody. Therapies targeting other immune signals may also be effective, and should be
explored depending on the results of earlier experiments. In theory, immune checkpoint
inhibition combined with ADI-PEG20 may also be effective against tumors that are already
susceptible to immune attack, although the addition of immunotherapy may make a smaller
difference in this case.
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4.4 Conclusions
As detailed here, the research done for this dissertation has opened many promising avenues for
future research. The paths to be taken are clear and vary widely. There are opportunities to
expand on the concept of the arginine sensor to develop better methods for monitoring cellular
responses to amino acid deprivation. The discovery of a new mechanism of long-term resistance
to arginine deprivation would benefit from further elucidation of both the in vivo mechanism and
the prevalence and relative contribution of the mechanism in other cancers and during clinical
arginine deprivation therapy. This new resistance mechanism also underscores the importance of
finding effective therapies to use in combination with ADI-PEG20 to eradicate tumors rather
than just slowing their growth. One promising direction, suggested by the observed increased
immune infiltration caused by ADI-PEG20, is to explore the combination of arginine deprivation
with immunotherapy, as described in this chapter. Overall, the work presented in this dissertation
has contributed greatly to the understanding of resistance to arginine deprivation therapies while
providing a basis for many more exciting advances to be built upon.
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